Shiley Eye Institute
The Viterbi Family Department of Ophthalmology
UC San Diego Health
UC San Diego School of Medicine

FOR SIGHT
Annual Report 2022
Contents

08 SEI EXPANSION
10 RESTORING VISION
12 PRESTIGIOUS AWARD
03 Letters from Leaders
08 Highlights
13 SEI @ UCSD
20 Alumni Profiles
24 New Faculty
30 Faculty Spotlights
34 SEI Updates
53 2022 by the Numbers
54 Faculty
66 Residents & Fellows
69 Education
74 Grants & Clinical Trials
80 Giving

On the Cover | “Retinal Phantasm”
courtesy of Richard F. Spaide, MD, New York, NY
Dear Friends,

The past year has provided indisputable proof again that the Shiley Eye Institute (SEI) community can thrive even in the most challenging conditions. Adapting to the changing landscape in healthcare and in our world, we have remained focused and productive while maintaining our compassion, curiosity, and connectivity. Our staff, residents and fellows, researchers and clinicians never veered from their dedication to our primary missions in patient care excellence, groundbreaking discovery, and education, as well as their commitment to community service. Everyone who works and learns at the Shiley Eye Institute today contributes in a unique way to our environment, but we all share a commitment to excellence.

With the imminent groundbreaking of the Viterbi Family Vision Research Center, we are looking forward to accelerating our development of treatments and cures for preventable and blinding eye diseases in new state-of-the-art laboratory space and with the recruitment of key scientists. We particularly are grateful for the support of Hanna and Mark Gleiberman who have generously donated $20 million to fund the Hanna and Mark Gleiberman Center for Glaucoma Research that will be housed in the new Viterbi Vision Research Center.

As our clinical activities continue to grow, there has been an increasing need for additional space to house them. Through the generosity of Darlene Shiley and with additional support from UCSD Health, a major remodeling of the second floor of the Shiley Eye Center was unveiled on February 10. Not only will the clinical space grow by ~25%, but there will be additional procedural space and a new laser treatment center.

You can read about some of the highlights in the Annual Report, including:

• Appointment of another Viterbi-endowed chair and recruitment of four stellar new faculty members
• Updates from the Richard C. Atkinson Laboratory for Regenerative Ophthalmology and the Nixon Visions Foundation initiative
• Broadening outreach to enhance diversity, equity and inclusion within our team and patients
• Fascinating work and research into strabismus, smoking effects in glaucoma, AI use in research, physician wellness and building “bridges” throughout UCSD

Building on the commitment to our community, we also are excited to have a new Shiley EyeMobile for Children. Moreover, it is our hope to refurbish the established EyeMobile to provide similar services to underserved seniors in our community.

With the engagement and the support of our entire Shiley Eye Institute team, there indeed is a bright future for our patients. We could not be more grateful for the year after year continued support of our family and friends that power our missions. There is no limit to what we can achieve to translate our groundbreaking discoveries to our patients.

Robert N. Weinreb, MD
Chair and Distinguished Professor, Ophthalmology
Director, Shiley Eye Institute
Dear Friends,

In this report, we celebrate another impactful year of success for the Shiley Eye Institute and Viterbi Family Department of Ophthalmology, which continue to set the standard of excellence in innovative clinical care, education, community service and collaborative research in ophthalmology. These featured stories recognize our talented new faculty, spotlight collaborations across the UC San Diego Health system and the university campus, and focus on the latest research, groundbreaking discoveries and successful treatment outcomes. With this report, we are pleased to share the impressive – and often life-changing – results we have delivered for our valued patients.

Our impact is not limited to the UC San Diego Health campus. We continue to focus on expanding access to quality healthcare throughout our region. The new Shiley EyeMobile for Children, a 33-foot-long vision clinic on wheels, started rolling through the community to remove barriers to vision care for underserved children and their families. Equipped with two exam rooms and a waiting area, the EyeMobile offers eye care services at no cost with the goal to serve 20,000 children each year. And this is only one example of UC San Diego’s ongoing commitment to advancing health equity – one vision screening, one dilated eye exam, and one pair of glasses at a time.

This year, a $20 million gift from Hanna and Mark Gleiberman will establish the Hanna and Mark Gleiberman Center for Glaucoma Research focused on protecting and restoring the vision of those affected by glaucoma. Inside this center, thanks to the transformative generosity of Dr. Andrew Viterbi, we are breaking ground on the new Viterbi Family Vision Research Center, a hub for interdisciplinary ophthalmology research. And recently, plans were unveiled for the expansion of the Shiley Eye Institute, which will markedly increase access, expand research infrastructure, and provide world-class facilities to diagnose, treat and develop therapies for vision diseases. This expansion is made possible by the more than $20 million Darlene and her late husband Donald Shiley have generously donated throughout the years, establishing a remarkable and enduring legacy.

Every day, UC San Diego strives to be an impactful and accessible public asset and transform our society for the better. I extend my deepest gratitude to our generous supporters who make the vital work of world-class vision care possible in support of this commitment. Your partnership with UC San Diego and the Shiley Eye Institute drives new discoveries, accelerates treatments and cures, and improves patients’ lives in our region and all over the world. Because of our visionary supporters, the next great discoveries are within reach. Together, we will transform vision care well into the future.

With Kind Regards,

Pradeep K. Khosla, PhD
Chancellor, UC San Diego
Letter from the CEO

Dear Friends,

For many of our patients, the Shiley Eye Institute is their first encounter with the level of care provided by a renowned academic medical center such as UC San Diego Health. From the start, Shiley has been at the forefront of vision expertise and outstanding eye care. Our clinical teams and internationally recognized faculty advance the field of ophthalmology every day, from treating diabetic retinopathy and macular degeneration to exploring the progression of glaucoma using artificial intelligence or developing gene therapies that can restore vision. They consistently provide the future of eye care today at UC San Diego Health.

The tremendous growth of these services over the past 30-plus years underscores the many successful outcomes experienced by our thankful patients. Their satisfaction continues to drive demand. In turn, we continue to increase our ophthalmology offerings at every opportunity.

The future of eye care remains within our sights thanks to the generosity and continued partnership of Donald and Darlene Shiley. Darlene’s recent $10 million gift, along with the additional funds provided by UC San Diego Health, will create more clinical space and significantly increase patient access to our world-class clinical team.

The Shiley Eye Institute continues its legacy of impact. It inspired the creation of the Ratner Children’s Eye Center, the Hamilton Glaucoma Center, and the Viterbi Family Department of Ophthalmology building—opening right next door in 2025. And soon, researchers will be closer to finding ways to reverse the effects of glaucoma thanks to $20 million gift from Hanna and Mark Gleiberman to establish the Hanna and Mark Gleiberman Center for Glaucoma Research.

Because of the generous support of donors like you, UC San Diego Health will continue to drive exploration, innovation and serve our community with the same compassion we always have in new facilities that afford our patients every advantage. We can’t wait for you to experience the future of eye care at our transformed Shiley Eye Institute.

Patty Maysent, MPH, MBA
CEO, UC San Diego Health
The UC San Diego Viterbi Family Department of Ophthalmology at the Shiley Eye Institute offers treatment across all areas of eye care. Our world class clinicians, surgeons, scientists, trainees and staff are dedicated to excellence and providing the best possible patient care to prevent, treat and cure eye diseases. Our research is at the forefront of developing new methods to diagnose, save and restore vision. In addition to educating the leaders of tomorrow, we are committed to serving the San Diego and global community.
Executive Committee

ROBERT N. WEINREB, MD
CHAIR

NATALIE A. AFSHARI, MD
VICE CHAIR, EDUCATION

DON O. KIKKAWA, MD
EXECUTIVE VICE CHAIR, CLINICAL

WILLIAM FREEMAN, MD
VICE CHAIR

DAVID B. GRANET, MD
VICE CHAIR, PEDIATRIC OPHTHALMOLOGY

SALLY BAXTER, MD, MSc
DIVISION CHIEF, INFORMATICS AND DATA SCIENCE

LINDA ZANGWILL, PhD
INTERIM DIRECTOR, RESEARCH

CRAIG KISHABA, MBA
ADMINISTRATIVE VICE CHAIR

Top Row (L to R) Craig Kishaba, MBA, David B. Granet, MD, Sally Baxter, MD, MSc
Bottom Row (L to R) Natalie A. Afshari, MD, William Freeman, MD, Robert N. Weinreb, MD, Linda Zangwill, PhD, Don O. Kikkawa, MD
Distinguished guests and faculty attended the celebration announcing the Shiley Eye Institute (SEI) Clinical Expansion on February 10, 2023 with benefactor Darlene Shiley, Chancellor Pradeep K. Khosla, Vice Chancellor of Health Sciences John M. Carethers, MD, CEO of UC San Diego Health Patty Maysent and Robert N. Weinreb, MD, Director of the Shiley Eye Institute and Chair of the Viterbi Family Department of Ophthalmology in attendance.

Chancellor Khosla praised Mrs. Shiley’s long-term support of SEI through her most recent generous gift which made this expansion possible. Dr. Weinreb remarked on the Shileys’ history of support for SEI and their lasting legacy.
The finished renovations on the SEI second floor will add clinical space, ophthalmic procedure rooms, a refractive laser center and a microsurgery training center for residents and fellows. There also will be space to accommodate its ever-increasing high volume of patients more comfortably with this expansion which is expected to be completed in late 2024.

The Optometric Glaucoma Society (OGS) Scientific Meeting 2022 recognized for the first time a group as their Honoree - the many contributions of the faculty and staff at the Shiley Eye Institute, UC San Diego. Under the direction of Robert N. Weinreb, MD, Distinguished Professor and Chair, SEI's accomplishments in glaucoma research, education and glaucoma care excellence have established the standard of care.

As mentioned by Murray Singeret, OD, cofounder of the OGS, “the list of individuals who trained in glaucoma at the SEI and then went to lead other eye departments is legendary and a “Who’s Who of Eyecare”. Beginning almost forty years ago, the Hamilton Glaucoma Center at the SEI consistently has led the way in development of ophthalmic imaging.”

Other notable areas of innovation include the pioneering use of 24-hour IOP measurements, development of alternative perimetric techniques, laboratory and clinical studies of both the outflow pathways and also glaucoma neuroprotection, as well as application of artificial intelligence to glaucoma diagnostics.

Congratulations to SEI for this prestigious award!
Restoring Vision in Glaucoma

Researchers at the University of California San Diego are accelerating their efforts to reverse the vision loss of glaucoma, thanks to $20 million in support from Hanna and Mark Gleiberman. The gift will establish the Hanna and Mark Gleiberman Center for Glaucoma Research at UC San Diego.

The center will be housed within the Viterbi Family Vision Research Center at UC San Diego. The funds are designated to stimulate research on advanced glaucoma, with the ultimate goal of protecting and restoring the vision of those who suffer from the condition.

As someone who was diagnosed with glaucoma, Mark Gleiberman understands the need and urgency to find a cure. Glaucoma is caused by damage to the optic nerve and can progressively lead to blindness. Gleiberman receives ongoing care from Robert N. Weinreb, MD, chair and Distinguished Professor.
of Ophthalmology, Director of the Shiley Eye Institute and holder of the Morris Gleich, MD, Chair in Glaucoma at UC San Diego.

“We have seen the incredible work that is being done at the Shiley Eye Institute, both from a clinical and research perspective. I believe that the glaucoma team at Shiley, led by Dr. Weinreb, is truly a world leader,” said Gleiberman, who is founder and CEO of MG Properties. “Hanna and I hope that our donation will greatly assist in accelerating and enhancing the groundbreaking work already being done.”

In addition to establishing the new center, the Gleibermans’ gift will create three new endowed chairs — Hanna and Mark Gleiberman Chancellor’s Endowed Chair in Glaucoma Research I, II and III — to support the recruitment of exceptional vision scientists to the research team.

“UC San Diego has an established history as one of the nation’s top places for vision care and research, and this gift will serve to bolster even further the leading-edge work taking place to combat glaucoma,” said UC San Diego Chancellor Pradeep K. Khosla. “We are grateful to Hanna and Mark Gleiberman for their visionary support of this new center.

In recognition of their dedicated support of the campus, the Gleibermans were honored with the 2021 Chancellor’s Medal, one of the highest honors given by UC San Diego to recognize exceptional service in support of the university’s mission.

FINDING A CURE FOR GLAUCOMA

Glaucoma is the leading cause of irreversible blindness in people over 60 years of age, but it can affect patients of all ages, including children. The progressive eye disease affects more than 3 million people in the United States and 70 million individuals worldwide.

The Gleibermans’ donation will bolster efforts to find effective ways of restoring vision to glaucoma patients in whom optic nerve damage has already occurred.

Researchers will be investigating various potential treatments, including utilizing stem cells to promote optic nerve regeneration. Researchers will also look at how to protect patients’ existing vision by identifying and rescuing retinal ganglion cells that have not yet died due to the condition.

“We are so grateful to Hanna and Mark Gleiberman for making this generous investment,” said Weinreb, who will serve as the principal investigator. “Our team plans to consider therapeutic approaches that will help achieve the goal to restore the vision of those who suffer from glaucoma.”

According to Weinreb, the gift will help UC San Diego grow the team of vision scientists who will focus on glaucoma research with the goal of accelerating the delivery of laboratory discoveries to patients in the clinical setting. The three new endowed chairs will support the recruitment of top researchers in the field.

“We understand that to regenerate the optic nerve damage which has already occurred is no small task, and likely to be a research project taking many years,” said Gleiberman. “But we believe that the Shiley Eye Institute team is very well equipped to take this on with results which can potentially benefit millions of people worldwide.”
Robert N. Weinreb, MD Named as Recipient of the Laureate Award from the World Glaucoma Association

The Association’s highest honor, this biannual award recognizes “seminal research, meritorious service, leadership and mentorship, innovation, international contributions, public service, translation of science to practice, and lifetime achievement.”

Dr. Weinreb is Chair and Distinguished Professor of Ophthalmology at the University of California San Diego where he also is the Director of the Shiley Eye Institute, Distinguished Professor of Bioengineering, and holder of the Morris Gleich MD Chair of Glaucoma.

A graduate of Harvard Medical School, Dr. Weinreb is a clinician, a surgeon, scientist, mentor and educator. Patients from throughout the world seek his medical and surgical expertise. His clinical and research interests are diverse and range from the front to the back of the eye, including the diagnosis, as well as the medical and surgical treatment of glaucoma.

Dr. Weinreb has served as President of the Association for Research in Vision and Ophthalmology, World Glaucoma Association, American Glaucoma Society, American Glaucoma Society Foundation, and Latin American Glaucoma Society. He has trained and mentored more than 170 post-doctoral fellows including more than 20 department chairs and numerous professors in the US and throughout the world.

The Award will be presented at the biannual World Glaucoma Congress in Rome on June 28, 2023.

Comprised of 91 international glaucoma societies with more than 14,000 members, the World Glaucoma Association is a global organization for glaucoma science and care whose core purpose is to eliminate glaucoma-related disability worldwide.
SEI @ UCSD

The faculty at the Shiley Eye Institute and Viterbi Family Department of Ophthalmology is fortunate to collaborate on research projects with many areas across the UC San Diego campus. These partnerships often open doors to funding and new relationships with outside companies, but more importantly are translating our research into real world discoveries and treatments for patients with eye diseases and vision disorders.

K12 Scholars’ Mentors

New SEI faculty members Nathan L. Scott, MD, MPP and Christopher B. Toomey, MD, PhD were appointed as K12 Scholars in the Ophthalmology and Visual Sciences Career Development Program and Mentored Clinical Scientist Development Program at UC San Diego and sponsored by the National Eye Institute (NEI) part of the National Institutes of Health (NIH). The objective is to develop outstanding clinician scientists to successfully compete at the national level for NIH grants and emerge as leaders within academic ophthalmology.

Nathan L. Scott, MD, MPP, Assistant Professor, is training under the mentorship of J. Silvio Gutkind, PhD, Professor of Pharmacology, Associate Director, Basic Science, as part of his research into development of a new mouse model to study metastatic uveal melanoma. Dr. Scott hopes to expand his knowledge of state-of-the-art molecular biology techniques as well as to take advantage of newly established high throughput mouse genetic models and RNA sequencing, single cell genetic analysis, and gene editing technologies (including CRISPR-Cas9 screens) and bioinformatics analysis. Working in the Gutkind Lab, Dr. Scott’s goals are to train in the highly relevant scientific environment, improving his critical thinking about ethical issues and regulations in biotechnology—ultimately becoming an independent investigator.

Christopher B. Toomey, MD, PhD, Assistant Professor, is training under the primary mentorship of Jeffrey D. Esko, PhD, Distinguished Professor, Department of Cellular and Molecular Medicine and Founding Director, Glycobiology Research and Training Center and co-mentor Radha Ayyagari, PhD, Professor of Ophthalmology and Pathology, Chief of Ophthalmic Molecular Genetics Laboratory (CLIA certified), Director of Shiley Eye Institute BioBank and Viterbi Family Chair III. Working within the Glycobiology Research and Training Center, Dr. Toomey will gain advanced training in glycobiology, in addition to advanced training in CRISPR/Cas9 and viral approaches to modifying gene expression, training in lipoprotein biology, and advanced training in electron microscopy analysis.
Gene Therapy

At the November 2022 Clinical Trials in Gene Therapy Symposium part of the French American Innovation Day (FAID) hosted by UC San Diego School of Medicine, the Embassy of France and Assistance Publique-Hopitaux de Paris, researchers and physicians discussed clinical trial collaborations and treatments in gene therapy in the U.S. and abroad. Gene therapy repairs or replaces a defective gene to treat or cure a disease caused by an abnormality.

At UC San Diego, there is a diverse group of scientists and physicians exploring the potential of gene therapy to treat a myriad of conditions.

Featured speaker in the Eye Disorders section of the symposium, Shyamanga Borooah, MD, PhD, Assistant Professor in the Viterbi Family Department of Ophthalmology, spoke about gene therapies for inherited retinal degeneration.

He stated, “The eye is an ideal target organ for gene therapy because it is easy to access and monitor, separated from the systemic circulation and relatively immunosuppressed.”

Dr. Borooah is working on gene therapies to test novel treatments in stem cell models of eye “diseases in a dish.” This is part of the work he oversees in a clinic that diagnoses and treats patients with retinal, macular and inherited diseases.

“Gene therapy has had a profound impact in my precision ophthalmology and ophthalmic genetics clinic,” said Borooah. “Previously, the main function of the clinic was to diagnose patients and provide low-vision support. Now the paradigm has shifted, and the question is often which treatment or which gene therapy trial patients can participate in. Gene therapy has not only given hope but has also restored vision in specific cases.”

More research needs to be done, and typically, gene therapy is offered only as part of clinical trials at places like UC San Diego.
Sally Baxter, MD, MSc, Assistant Professor of Ophthalmology and Biomedical Informatics at UC San Diego published a paper in the Journal of American Medical Association (JAMA) Open Network titled “Association of Electronic Health Record Inbasket Message Characteristics with Physician Burnout.” The research team looked at how the number of messages physicians receive in their “in-basket” as well as the quality/content of those messages may affect their wellbeing and possibly cause burnout.

Dr. Baxter and colleagues at UC San Diego Health discovered that there is a correlation in the high number of messages in the in-basket of physicians who self-identified themselves as feeling burnout. Because many healthcare providers use electronic health records (EHR), patients have more access to messaging their providers.

The researchers analyzed more than 1.4 million messages sent to 609 physicians. About half the physicians considered themselves as burned out. These physicians had a higher volume of messages in their in-basket. The content of the messages, whether they were positive, negative, or contained expletives and violent language, did not influence the physicians’ feelings of burnout. However, the findings showed that younger, female, and Hispanic/Latino physicians were more likely to be in the group considering themselves as burned out.

The study used natural language processing (NLP), which is a branch of computer science using artificial intelligence (AI) to give computers the ability to understand text and spoken words like human beings. Using NLP, researchers believe it can help with the negative messages received through automated in-basket filters, analysis of patients’ frustrations to find out what caused the frustrations, and ways to improve the patient experience.
New Strabismus Treatments

There are six muscles in the eye that help move your eyes and focus on the same object. This is what normally happens, but when the muscles do not work together, strabismus occurs.

Strabismus is a disorder resulting in the misalignment of the eyes, and the eyes do not appear to be working together. Untreated strabismus is highly correlated with amblyopia, one of the most common causes of irreversible vision loss in children, and strabismus has a significant impact on the quality of life in children and in adults.

Jolene Rudell, MD, PhD, Assistant Professor of Ophthalmology at the SEI Ratner Children’s Eye Center, recently received a generous grant from the Strabismus Research Foundation in San Francisco to investigate using local injections of bupivacaine in the extraocular muscles of patients with strabismus. Bupivacaine is a local anesthetic that has been used to numb parts of the body during or after surgery or other procedures. Its use has been effective in treatment for strabismus.

“The specific mechanism for why bupivacaine works is still unknown,” said Dr. Rudell. Her work will investigate why bupivacaine works for strabismus and to understand the biology of effective treatments for patients. Dr. Rudell has been studying the biology of strabismus and extraocular muscles since she was in residency training.

The lack of treatments for strabismus and the highly unpredictable and variable rates of success of more invasive surgeries on extraocular muscles have fueled Dr. Rudell’s desire to learn more about the pathogenesis of strabismus in search of treatments for her patients. She believes the lack of knowledge about the pathogenesis of strabismus is a key factor in our inability to treat it effectively. Her career goal is to better understand this disease and to find effective treatments to help patients.

Joining her in this research project will be Marianna Alperin, MD, Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences with the UC San Diego School of Medicine, who specializes in skeletal muscle biology and is an expert in muscle physiology and biometrics, muscle stem cell biology, and muscle disease. Dr. Rudell will also be collaborating with Joel Miller, PhD, Director of Research and Senior Scientist at the Strabismus Research Foundation, and Linda McLoon, PhD, Professor, Department of Ophthalmology and Visual Neurosciences at the University of Minnesota Medical School.
Bridge 2AI

Assistant Professor Sally L. Baxter, MD, MSc, and Professor Linda Zangwill, PhD, are part of a UC San Diego School of Medicine group selected for the National Institutes of Health (NIH) Common Fund’s Bridge to Artificial Intelligence (Bridge2AI) program. The team at the Shiley Eye Institute was selected to participate in the project due to a long-standing track record of innovation and excellence in eye imaging and conducting clinical research studies.

The NIH’s Bridge2AI funding is intended to speed up the widespread use of AI in biomedical research and health care. It has been noted that AI has potential in helping understand and treat disease, but its clinical and research use remains limited because AI cannot be easily or appropriately applied to new datasets. Bridge2AI will create comprehensive AI-ready datasets to be the foundation for new, interpretable and trustworthy AI technologies to answer these issues.

Drs. Baxter and Zangwill are leaders in the modules associated with a data generation project focused on salutogenesis or the origins of health called AI-READI (AI Ready and Equitable Atlas for Diabetes Insights), along with principal investigators from the University of Washington. Both investigators at SEI will lead the Skills and Workforce Development Module and the Data Acquisition module at UC San Diego. The Skills and Workforce development module also includes faculty from the UC San Diego Halıcıoğlu Data Science Institute and Herbert Wertheim School of Public Health and Human Longevity Science.

The AI-READI study will focus on diabetes—to learn how diabetes is influenced by patients’ genes, lifestyle and environments by generating an ethically sourced data repository to develop machine learning models.

The AI-READI project will include eye imaging and eye exam findings as part of the data being collected in the study, alongside a wide range of other data, including laboratory tests, physical measurements, surveys/questionnaires, electrocardiograms, genetic data, and statistics from digital health devices like activity trackers. The hope is that researchers can use this wide range of information to generate new insights about diabetes risk and progression, to help develop better treatments for diabetes and its manifestations in different areas of the body, including the eyes.

Focusing on recruiting people traditionally underrepresented in the biomedical sciences and data science/AI workforce, the Skills and Workforce Development team will create a mentored research training program to diversify the AI workforce. Trainees will go through a structured “bootcamp” to learn AI and programming skills along with longitudinal curriculum that incorporates principles of clinical research, AI/machine learning, ethics and the responsible conduct of research. Ultimately, training and educational materials will be developed for the broader community of researchers who will use the AI-READI dataset.
Upon the establishment of the Viterbi Family Department of Ophthalmology with a generous $50 million donation by Andrew Viterbi, PhD, six endowed chairs were established as well as the soon to be constructed Viterbi Family Vision Research Center. Recently, Robert N. Weinreb, MD, Chair, Viterbi Department of Ophthalmology and Director, Shiley Eye Institute (SEI), announced the appointment of Eric Nudleman, MD, PhD as the inaugural Viterbi Family Chair for Retinal Vascular Diseases.

Eric D. Nudleman, MD, PhD, Associate Professor of Clinical Ophthalmology, joined the retina service at SEI eight years ago. His clinical focus is on vitreoretinal diseases and surgery, with a special interest in pediatric vitreoretinopathies. His laboratory focuses on developmental angiogenesis and the role of the Wnt signaling pathway with a particular interest in identifying novel targets to treat vascular diseases.

The award of this chair allows Dr. Nudleman to continue his groundbreaking research to identify specific molecules that are required for maintaining the integrity of the blood-retina barrier that regulate vascular proliferation.
Dr. Nudleman graduated from Stanford University with his bachelors and doctoral degrees and then received his medical degree from Albert Einstein College of Medicine at Yeshiva University. He is also the recipient of many prestigious honors such as the Ronald G. Michels Fellowship, Heed Fellowship, the Doris P. and Harry I. Wexler Prize, Rosenbaum Research Award, and the Association of University Professors of Ophthalmology/Research to Prevent Blindness Resident and Fellow Research Forum Award.

The Viterbi Family Chair for Retinal Vascular Diseases was commemorated with an event at the UC San Diego Audrey Geisel University House on Monday, November 28, 2022. Hosted by Chancellor Pradeep K. Khosla and Associate of the Chancellor, Thespine Kavoulakis, the celebration was attended by family and friends of both Drs. Viterbi and Nudleman.

*Chancellor Pradeep K. Khosla, Eric Nudleman, MD, PhD, Andrew Viterbi, PhD & Robert N. Weinreb, MD*

*Lindsay Nudleman and Eric Nudleman, MD, PhD*

*Andrew Viterbi, PhD and Chancellor Pradeep K. Khosla*
When Christopher Girkin, MD, MSPH trained as a glaucoma fellow here at the UC San Diego Shiley Eye Institute (SEI), he saw how translational research could impact patients’ lives. With SEI’s pioneering work in optic nerve and retinal imaging, Dr. Girkin learned methods of research and use of clinical imaging techniques that he would later deploy when he moved on to the University of Alabama at Birmingham (UAB).

At UAB, Dr. Girkin expanded their clinical studies to include the at-risk African American population as part of a National Institutes of Health (NIH) funded training grant with mentors from UAB and UC San Diego. His collaboration included Robert N. Weinreb, MD, Linda Zangwill, PhD, and Pamela Sample, PhD from SEI, as well as colleagues at UAB and Columbia University. This collaboration became the African Descent and Glaucoma Evaluation Study (ADAGES).

Growing up in the South, Dr. Girkin experienced what he called the “palpable deep racial divide in our culture.” These experiences, along with the inequalities in care delivery seen during medical training, led him to focus his early career on developing a health disparities program.

“For me, working in broad scientific collaborations is the greatest pleasure in academia. We get to surround ourselves with brilliant but very different minds focused on finding solutions to the same problem,” said Dr. Girkin.

Dr. Girkin recently stepped down as the Chair of the ophthalmology department at UAB after 10 years to devote his time to his research in imaging and the Living Eye Project. When he first arrived at UAB in 1999, he founded the glaucoma service and fellowship program. As chair, Dr. Girkin developed a partnership with the EyeSight Foundation of Alabama to
invest in vision research and grow the department.

The bulk of Dr. Girkin's work now focuses on developing and expanding the Living Eye Project. He began the program seven years ago to develop a platform for vision research with research-consented organ donors; it has supported several ongoing NIH-sponsored projects. With the remainder of his time, Dr. Girkin enjoys training clinical fellows and working on his collaborative research program that extends across imaging studies, adherence, ocular biomechanics, outcomes and health services research.

Outside of work, he spends time with his two boys and his wife, a child psychiatrist. They enjoy mountain biking, scuba diving, traveling with family and friends, and hiking.

Andrew Camp, MD has been named the Acting Chief of the Ophthalmology Section at the Veterans Administration (VA) Medical Center in La Jolla as of October 2022. His duties include clinical oversight, development and expansion of the ophthalmology section. His goals are to raise patient satisfaction by improving clinical efficiency, increase patient volume and promote research within the VA ophthalmology section.

Dr. Camp is an assistant professor in the Viterbi Family Department of Ophthalmology teaching medical students, residents and fellows at the UC San Diego School of Medicine. He completed his glaucoma fellowship at SEI.

Dr. Camp's clinical focus is the medical and surgical management of adult and childhood glaucoma. His research focuses on the diagnostic testing and treatment options for glaucoma patients.
Patients rely heavily on and place a lot of trust in their doctors. Ningli Wang, MD, PhD, Director of the Beijing Tongren Eye Center, was reminded of this while realizing the importance of a physician’s responsibility in his patient’s treatment. This realization came years ago while treating a blind glaucoma patient who had one eye with high intraocular pressure and a shallow anterior chamber in the other eye. This patient lived in a remote area of China and Dr. Wang had been part of a team doing consultation in the area. Due to miscommunication, there was an error in treatment by a local doctor. The patient was transferred to the Beijing hospital for treatment under Dr. Wang's care and after multiple surgeries, the patient finally had his vision restored to 20/20 and the lens was preserved. To this day, this incident and patient has stayed with him, as he has devoted himself to promoting eye health in China.
Ophthalmology was not his first choice in fields of study during medical school at the Medical College of Qinghai University. But Dr. Wang considers it his “great cause” to help the blind see again. He is devoted to the clinical and scientific research of glaucoma and prevention of blindness. That is what led him to the UC San Diego Shiley Eye Institute (SEI) in 1998 as a post-doctoral international fellow following his studies and work at Zhongshan School of Medicine. When he studied for his PhD, Dr. Wang was involved with clinical applications more so than basic research. His time at SEI exposed him more to experimental research. The experimental techniques he learned helped lay the foundation for his scientific research.

Dr. Wang credits Robert N. Weinreb, MD, Director of SEI and Chair of the Viterbi Family Department of Ophthalmology, whose “careful teaching and selfless sharing” showed him how to be an exceptional leader and manager.

After arriving at Tongren Hospital and founding the Beijing Tongren Eye Center, Dr. Wang orchestrated the growth of the eye center and its influence in clinical and scientific vision research in China. He was president of the Tongren Hospital from 2016-2017 and is the current president of Asia-Pacific Ophthalmology Academy. His work in preventing trachoma and cataract blindness garnered him a Vision Excellence Award from the International Agency on the Prevention of Blindness (IAPB). Dr. Wang's work to have primary eye care incorporated into primary health care—including adding cataract surgery to the national basic medical insurance—was also noted. Dr. Wang also leads a tele-ophthalmic center across 200 hospitals nationwide for remote consultation and collaborative treatment.

Dr. Wang considers his greatest contribution in ophthalmology to be his research on trans-lamina cribrosa pressure theory, which explains the optic nerve injury in normal tension glaucoma patients and showed that intracranial pressure was a risk factor. The next big advance in ophthalmology will be in visual augmented reality, Dr. Wang believes. Institutions and industries are increasingly allocating more resources into development of contact lenses that apply augmented reality technology to video recording, accessing information, diagnosing and treating diseases.

Currently, he spends the majority of time on research with one day of the week devoted to seeing patients in the clinic. During his free time, Dr. Wang enjoys cycling. He participated in the Tour of Qinghai Lake International Road Cycling Race and plans on completing 40,000 kilometers (approximately 24,850 miles) of cycling in the future. For him, cycling is more than a way to improve physical endurance; it’s also about perseverance and courage to rise to the occasion.
The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute (SEI) welcomes Nathan L. Scott, MD, MPP as Assistant Professor of Ophthalmology and the Inaugural Chief of the Ocular Oncology Division.

Dr. Scott is a physician-scientist with a clinical focus on vitreoretinal diseases and surgery, specializing in ocular oncology. His clinical research and interests include utilizing imaging and genomic/molecular technologies to better understand, diagnose and treat cancers of the eye. He treats general and complex vitreoretinal diseases as well as both surface and intraocular malignancies.

Dr. Scott earned his medical degree at Harvard Medical School and completed his residency in ophthalmology at the University of Miami Bascom Palmer Eye Institute, where he was also Chief Resident. Dr. Scott also holds a Master in Public Policy from the Kennedy School at Harvard University. He completed fellowships in Vitreoretinal Surgery and Ocular Oncology at the Bascom Palmer Eye Institute. He received multiple awards during his training, including the Heed Ophthalmic Society Fellowship, the Mary August Trust Fellowship Award, the 2020 Vit Buckle Society Fellows Foray Award, and the American Academy of Ophthalmology Robert Copeland Fellowship Award.

Dr. Scott was appointed as a K12 Program Scholar from the National Eye Institute (NEI) Mentored Clinical Scientist Development Program Award at UC San Diego.

Dr. Scott is actively engaged with the American Academy of Ophthalmology, where he serves on the executive board of the minority ophthalmology mentoring (MOM) program and is a member of the young ophthalmology advocacy sub-committee.
New Division of Ocular Oncology

The Shiley Eye Institute’s (SEI) new division of Ocular Oncology offers treatments for eye cancer which can affect the surface of the eye, areas surrounding the eye and structures within the eye. Nathan L. Scott, MD, MPP, who recently joined SEI, is the Inaugural Chief of the Ocular Oncology Division.

SEI’s team of specialists includes oculoplastics, neurosurgery, adult and pediatric medical oncologists, as well as radiation oncologists at the world-renowned UC San Diego Health Moores Cancer Center. The team treats both adult and pediatric eye cancers. The team prides itself on their ability to promptly see patients in need with an emphasis on personalized treatment plans.

The SEI ocular oncology service offers comprehensive eye care that incorporates cutting edge diagnostic imaging, advanced treatment options, and a multi-disciplinary approach to individualized patient care. The ocular oncology service provides:

Cutting Edge Diagnostic Imaging
- Fundus Photography
- Fluoresceine Angiography
- ICG Angiography
- Optical Coherence Tomography (OCT)
- Ocular Ultrasound (B Scan)

Advanced Treatment Options
- Plaque Brachytherapy
- Radiation Therapy
- Systemic and Local Chemotherapy
- Tumor Resection

Related Conditions Treated
- Conjunctival Tumors (Ocular Surface Squamous Neoplasia, Melanoma, Carcinoma)
- Anterior Segment and Iris Tumors
- Lymphoma of the Eye and Orbit
- Uveal Tumors (Melanoma, Metastatic tumors, Vascular tumors)
- Vascular Tumors (Choroidal Hemangioma, Capillary Hemangioma)
- Eyelid and Orbital Tumors
- Retinoblastoma
The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute (SEI) at UC San Diego welcomes Christopher B. Toomey, MD, PhD, as Assistant Professor of Ophthalmology. Dr. Toomey specializes in the diagnoses and treatment of adult vitreoretinal disease, macular degeneration, diabetic retinopathy, retinal detachment, macular holes, and other retinal diseases.

While completing his medical and doctoral degrees at Duke University School of Medicine, Dr. Toomey was part of the integrated National Institutes of Health (NIH) funded medical scientist training program. He received his residency training at SEI following medical school. Rounding out his medical training, Dr. Toomey did his two-year fellowship in vitreoretinal surgery at the Wilmer Eye Institute, John Hopkins Hospital in Baltimore. As a young clinician scientist, he already has received multiple prestigious awards including the Heed Ophthalmic Society Fellowship, VitreoRetinal Surgery Foundation Research Award and has served on the editorial board of the Journal of Clinical Investigation (JCI), as a JCI scholar.

As a physician-scientist, he is focusing on age-related macular degeneration (AMD) and other retina and vitreous eye diseases. Dr. Toomey is participating in a research program studying the early and intermediate stages of “dry” AMD. Approximately 50% of the attributable risk of developing AMD is due to common polymorphisms in complement regulatory genes. His research discovered the mechanism of complement factor H in regulating the formation of drusen in patients with AMD (published in Proceedings of the National Academy of Sciences and reviewed in Progress in Retinal and Eye Research). As a part of this discovery, Dr. Toomey explained an unexpected role of extracellular glycosaminoglycans (repeating disaccharide sugar chains) in regulating the formation of drusen.
Dr. Toomey was appointed as a K12 Program Scholar from the National Eye Institute (NEI) Mentored Clinical Scientist Development Program Award at UC San Diego.

His laboratory program is embedded within the Glycobiology Research and Training Center at UC San Diego, to determine the pharmacological potential of glycosaminoglycans in patients with early and intermediate stages of “dry” AMD. His long-term goal is to develop therapies capable of cleansing the eye of drusen prior to development of vision loss in AMD.

Prestigious Honors

As part of Dr. Christopher Toomey’s research into AMD, he has been awarded a $100,000 scholarship from the Robert Machemer, MD and International Retinal Research Foundation Fellowship. Robert Machemer is considered the father of modern vitreoretinal surgery—with discoveries such as the breakthrough technique, pars plana vitrectomy.

The Robert Machemer Foundation Fellowship Board, consisting of top leaders in the field of vitreoretinal surgery, chose one junior vitreoretinal clinician-scientist as the recipient for this award in support promising early career research of the retina. Dr. Toomey’s research project is called Ultrastructural Glycomics Analysis of Bruch’s Membrane in Age-related Macular Degeneration (AMD).

In addition, Dr. Toomey recently presented his research on drusen formation in patients with AMD as part of the Alliance for Eye and Vision Research (AEVR) Emerging Vision Scientists (EVS) Day on Capitol Hill. As one of 21 EVSs in attendance, Dr. Toomey visited the San Diego US Representative congressional office to advocate for the National Eye Institute’s (NEI) budget.

The NEI is part of the National Institutes of Health (NIH). The program by AEVR occurred during the annual International AMD Awareness Week Congressional Briefing, with the 21 EVSs showing posters of their research at a Congressional reception. These educational and advocacy activities are part of an effort to spur breakthrough research to prevent, delay, and treat vision disorders.
New Faculty
Cristiana Vasile, MD, MAS

The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute (SEI) welcomes Cristiana Vasile, MD, MAS as an Associate Clinical Professor of Ophthalmology. Dr. Vasile is a Board-Certified Ophthalmologist and fellowship trained Glaucoma specialist.

Dr. Vasile spent several years at the SEI Hamilton Glaucoma Center performing vision research. She served as the founding Director of the UC San Diego Optic Nerve Reading Center, a hub for collaborative research conducted by national and international glaucoma centers.

Following her internship in Internal Medicine at UC San Diego, she completed a residency in Ophthalmology at the UC San Diego Shiley Eye Institute. During her residency, she received the Department of Ophthalmology Resident Research Award. She subsequently completed a Glaucoma Fellowship at UC San Diego. Dr. Vasile also was awarded a Masters in Advanced Studies (MAS) in Clinical Research at UC San Diego.

Dr. Vasile is dedicated to outstanding and compassionate care of her glaucoma patients.

She speaks several languages including English, Italian, French, Romanian and also is proficient in Spanish.
I retired from the high-tech industry last year and have been dabbling in photography for over eight years. Vision is extremely important to me.

Dr. Cristiana Vasile's greatest strength (after her glaucoma expertise!) is her exceptional communication skills. I think that the most important aspect of communication is listening, and she is a wonderful listener. She is the only ophthalmologist I have ever worked with who took the time to genuinely listen to my thoughts and concerns. She was patient and thoughtful in how she communicated with me and I am truly grateful for that. Not just high IQ but, just as importantly, high EQ.

Dr. Vasile always responds promptly to my queries online as well, and once she did so even when she was on vacation - totally unexpected. She is devoted to her patients!

When I recently moved to Colorado, Dr. Vasile was able to connect me with an exceptional ophthalmologist who normally does not take on any new patients. He only did so at her request, which also tells you something about the respect she enjoys in the extended ophthalmology community.

I am truly grateful for all she has done for me. Here is a photo I took recently.

-Joe

---

The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute (SEI) welcomes **Manuel Puig-Llano, MD, FACS, FASRS** as Clinical Professor of Ophthalmology.

Dr. Puig-Llano's completed an Ophthalmology Residency and Fellowships in Cornea and Retina Vitreous at the University of California, San Francisco and received his medical degree from the National Autonomous University of Mexico. His career in ophthalmology began as a teenager working with his father doing ophthalmology clinical research. His father, who studied ophthalmology in Vienna, inspired him to pursue this area of medicine.

After working at his father's ophthalmology practice for six years in Mexico, Dr. Puig-Llano opened a clinic in Chula Vista. He treated patients for nearly 40 years in this office before joining SEI.

Dr. Puig-Llano's devotion to treating the underserved populations in Southern California extended to medical missions in the Philippines and Mexico to treat patients with diabetic retinopathy and glaucoma. On these missions, Dr. Puig-Llano brought equipment, supplies and assistance where he built community relations and learned to speak Tagalog.

He is fluent in English and Spanish.
Faculty Spotlight
Shira L. Robbins, MD, FAAO, FAAP

Shira L. Robbins, MD, FAAO, FAAP is a Clinical Professor who specializes in Pediatric Ophthalmology and Adult Eye Re-Alignment in the Anne F. and Abraham Ratner Children’s Eye Center at the UC San Diego Shiley Eye Institute (SEI) and Viterbi Family Department of Ophthalmology. She currently serves as Vice President Medical Staff for UC San Diego Health, the Director of Neonatal Ophthalmology at the Jacobs Medical Center NICU and Educational Director for the Division of Pediatric Ophthalmology and Strabismus.

After receiving her medical degree from the Medical College of Pennsylvania Hospital and completing her residency in ophthalmology at Hahnemann University Hospital in Philadelphia, Dr. Robbins completed her fellowship training in pediatric ophthalmology at UC San Diego and the Naval Medical Center in San Diego. She is board certified by the American Board of Ophthalmology and is a Fellow of both the American Academy of Ophthalmology and the American Academy of Pediatrics.

Dr. Robbins’ practice focuses exclusively on pediatric ophthalmology and adult eye re-alignment. Her clinical interests encompass pediatric patients with vision and ocular complaints, amblyopia, strabismus (eye misalignment), retinopathy of prematurity, pediatric glaucoma and cataracts (including intraocular lens placement), congenital eye syndromes, craniofacial syndromes, nystagmus, learning disabilities, nasolacrimal tear duct disorders, genetic ocular disorders, and systemic diseases affecting the eyes. Her adult practice includes patients with double vision, strabismus, and visual strain complaints.

Dr. Robbins performs research to preserve and protect the vision of premature children. Her research targets improving how doctors diagnose, prevent and treat blinding diseases in the smallest most vulnerable of infants.
WHY DID YOU GO INTO MEDICINE?
During my first career as a genetic researcher, I found that I was drawn to working in a more direct and immediate way to help people. My initial desire to be a primary care doctor changed when I realized I could create such rapid impact in a person’s life through the elegance of eye surgery.

HAVE ANY OF YOUR PATIENTS AFFECTED YOU SIGNIFICANTLY?
The courage of so many of my patients remains a lasting impression. One early example was a young boy who was hospitalized after a stroke related to sickle cell anemia. Upon admission this child could not walk or talk. Within days, I witnessed him run next to his IV pole then jump onto the metal wheeled base taking it for a ride down the hallway of the hospital. The absolute will to live and play after such a serious health crisis gave me much admiration for this little boy. Unfortunately, the unit nurse was not so amused and asked me to stop my patient from “disrupting the ward.” To the nurse’s dismay, I told my patient that he could have one more ride before he needed to get back in bed; after all, it was 2 am. I will remember his smile forever.

HOW DO COLLABORATIONS AND PARTNERSHIPS FIT INTO YOUR ROLE AS A RESEARCHER?
Being a team player is one of the main reasons that drew me to academics. The opportunity to work as a team allows me to do broader and deeper research. My collaborations with the Neonatal ICU have allowed me to study potential treatments to avoid blindness in these infants as well as care for them in the hospital every week. My most important partnership would be with my husband who takes care of the home front allowing me the opportunity to be a productive academic surgeon.

WHAT ARE YOUR MOST IMPORTANT/SIGNIFICANT TEACHING OR RESEARCH CONTRIBUTIONS?
From a research perspective, some of my most impactful work as an academic surgeon has been to help create the national guidelines for diagnosis and treatment of the blinding disease retinopathy of prematurity. Guidelines across the globe are based on this paper.

From a teaching perspective, my training of American and International fellows who go on to care for many patients worldwide expands my influence. Additionally, I created the first teaching program to train ophthalmology residents to break bad news to patients and their families in a respectful and effective way.

WHAT DO YOU DO IN YOUR FREE TIME?
My most significant life contribution are my children. In our free time, my husband and I spend time with them as they pursue their interests. For my little one that means lots of time on the soccer field sidelines. For my older one, that means reading their creative writing and other academic pursuits. Together we love to hike, swim, watch British mystery shows, and play with our ridiculously spoiled dog. I am an avid tennis fan and a forever Philadelphia Eagles fan wearing a championship cap for a week straight when they won the Super Bowl. You have to bask in the glory when you can!
Chris W. Heichel, MD is a Professor of Clinical Ophthalmology in the Division of Cornea, Cataract and Refractive Surgery at the UC San Diego Shiley Eye Institute (SEI) and Viterbi Family Department of Ophthalmology.

After completing his medical degree with honors from Chicago Medical School in 1999, Dr. Heichel became chief resident in ophthalmology at UC San Diego in 2000 and completed a cornea fellowship at SEI in 2004. He joined the SEI faculty in 2004 and has been consistently named a top doctor by U.S. News & World Report.

In his clinical practice, Dr. Heichel enjoys challenging cataract and anterior segment cases including traumatic cataracts, pediatric cataracts, subluxed lenses, dislocated intraocular lenses, and iris reconstruction cases. He is well versed in a breadth of keratoplasty techniques including endothelial (DMEK, DSAEK, DWEK), penetrating (PKP), lamellar (DALK), artificial (KPRO), and limbal stem cell transplantation. He takes a special interest in treating congenital corneal opacities and has extensive experience in pediatric corneal transplantation. He practices the most advanced laser refractive surgery techniques for LASIK and PRK, as well as phakic intraocular lenses like the Visian ICL, INTACS and corneal cross-linking.

As a physician, Dr. Heichel’s patients are his priority, but he is very dedicated in teaching and training fellows and residents. This is evidenced by the numerous awards he has received for Teacher of the Year.

WHY DID YOU GO INTO MEDICINE?
Witnessing a tragic accident during college convinced me to go into medicine. After desperately attempting to save a good friend’s life, I distinctly remember feeling helpless. That moment stuck with me and from that point on I have dedicated my life to helping others and never feeling that way again.
HAVE ANY OF YOUR PATIENTS AFFECTED YOU SIGNIFICANTLY?
I remember a young single mother who developed traumatic cataracts from a domestic violence incident, which made it difficult for her to hold down her job and feed her children. She did not have money or insurance to pay for the surgery, so I performed it pro bono. Her successful outcome enabled her to continue working and to care for her family. Seeing her tears of joy will stay with me forever.

Another patient was a 12-year-old who was diagnosed with keratoconus (the cornea thins and gradually bulges out into a cone shape causing blurred vision). She struggled to see and as a result fell behind in school. I performed bilateral corneal transplantation on her many years ago, and last year I received an announcement for her graduation from medical school.

Also, I was asked to perform the first pediatric cataract surgery in the U.S. on a 3-year-old lowland gorilla at the San Diego Zoo Safari Park. Working collaboratively with veterinarians, keepers and surgical staff in order to successfully plan, organize, and perform surgery was one of the most rewarding moments of my career... and quite possibly the most unique.

HOW DO COLLABORATIONS AND PARTNERSHIPS FIT INTO YOUR FIELD?
Collaboration is critical in our research. Fortunately, some of the brightest minds in ophthalmology are here at UC San Diego. My research is primarily focused on corneal transplantation with an emphasis on pediatric patients. There are only a handful of trained pediatric cornea specialists in the world that can successfully perform transplants in these patients, and I was fortunate to be trained by Shiley’s own Stuart I. Brown, MD. Families frequently travel across the globe to find one of us to help their children and it brings me great joy to be able to provide these families hope. Developing new techniques and protocols to increase the success of these procedures in my patients and patients worldwide will always drive me. I am grateful for the continued funding and support that makes this possible.

WHAT DO YOU SEE AS THE NEXT BIG ADVANCES IN YOUR FIELD?
Stem cells will be very important. Corneal and cataract surgery will change dramatically when we advance stem cell technology and transplantation to become predictable, repeatable and successful enough for routine use. While both corneal transplantation and cataract surgery are already widely successful, the ability to restore and improve sight with a less invasive procedure and a faster recovery will propel ophthalmology to the next level.

WHAT DO YOU DO IN YOUR FREE TIME?
Outside of medicine, my two greatest passions are my family and traveling. I love the time I have with my amazing wife and daughters. Like many parents, I enjoy the simplicity of being on the sidelines at my daughters’ soccer games, and I cherish our times together at the beach or on the slopes. I love exploring other parts of this world: how others eat, think, and live. Travel is inspiring and illuminating, and I love getting to experience new places through my children’s eyes. Likewise, traveling to perform medical mission work abroad has been beyond rewarding, and I look forward to more of this in the future.
Advancing Diversity & Inclusion at SEI

We are committed to cultivating a welcoming, inclusive environment for all patients, employees, faculty and trainees.

The UC San Diego Viterbi Family Department of Ophthalmology and Shiley Eye Institute (SEI) continues to promote diversity and inclusion in clinical activities, research, education and community service. A key addition to our Diversity, Equality, and Inclusion (DEI) Committee in 2022 was the appointment of Nathan Scott, MD, MPP as Co-Chair of the DEI Committee. He joins Sally Baxter, MD, MSc in leading diversity and inclusion initiatives at Shiley. Dr. Scott has long been an advocate for diversity and has served on the Executive Committee of Minority Ophthalmology Mentoring (MOM) Program, a program of the American Academy of Ophthalmology (AAO) in partnership with the Association of University Professors in Ophthalmology (AUPO), which provides one-on-one mentorship, guidance in medical career planning, networking opportunities, and access to educational resources to students who come from backgrounds that are underrepresented in medicine. Drs. Scott and Baxter have both served as MOM mentors to medical students across the country through this program. Dr. Scott will bring new perspectives and leadership to Shiley’s DEI efforts, positioning our department as a leading entity in this domain.

In 2022, the department also received two major educational training grants from the National Institutes of Health.
(NIH) to provide funding support and mentored research training opportunities to a diverse range of students. One grant, awarded by the National Eye Institute (NEI), provides support for medical students to complete short-term summer research projects to supplement their classroom and clinical training. Another grant is through the trans-NIH Bridge2AI initiative, which is funding a yearlong internship program to train interns from a wide range of backgrounds to learn about artificial intelligence, machine learning, and biomedical research principles, scheduled to start in summer 2023. Both programs will also offer networking and career development opportunities and are directed by Dr. Baxter and Linda Zangwill, PhD. Our department is one of the few nationwide to have NIH-funded training grants across multiple training stages, including training programs for medical students, graduate students, postdoctoral fellows, and early career faculty.

In addition, Shiley faculty, staff, and trainees continue to engage in local outreach activities, including hosting seminars with students regarding career paths in ophthalmology, providing care to underserved individuals through the UC San Diego Free Clinic and the Shiley EyeMobile for Children, and engaging in broader diversity-related initiatives at UC San Diego Health Sciences and the general campus.
When I was younger, I used to ride my bicycle 100 miles per week, but now at 84-years-old I’m happy to be walking five miles a week. My philosophy is to think about what you can do, don’t lament about what you can’t do—just open your front door.

I was diagnosed with glaucoma in 2008 and began treatment shortly after the diagnosis. A few years later, I had the first surgery for my left eye. I felt that my second ophthalmologist in San Diego did not know how to help with my vision loss. A friend thought I should find a clinic in San Diego that conducts clinical trials because my glaucoma was not responding to normal eye drops.

In the fall of 2018, I was teaching my last semester of a 20-year career as an adjunct English professor at Palomar College. I could not read my textbook,
so my friend came to my house every Sunday to read it to me. Another friend helped record the student grades. I also relied heavily on my father’s 3x5-inch magnifying glass to read recipes and newspapers. By December, I had to stop driving and a friend took me grocery shopping.

I started seeing Robert N. Weinreb, MD, who treated me with lasers, different eye drops, and surgery on my left eye. I then had an edema on my macula which Eric Nudleman, MD, PhD treated me for. In 2020, I was next referred to Natalie Afshari, MD for a corneal transplant in my right eye.

I was overjoyed by the corneal transplant, which required my daughter to fly in from Houston. This cornea surgery required me to lie flat for 24 hours with short breaks for food and bathroom. As the dutiful daughter she is, I was given meatloaf, an old family recipe, fresh vegetables, and salad. I am a slow eater and wanted to finish each meal, so she would say, “Mother, your time is up! You must lie flat now!” My daughter was worried that it would be her fault if the surgery was not successful because I was not flat on my back long enough.

After careful maneuvering, we were pleased to learn the surgery was a success! I could see immediately and seven days later my vision was crisp and clear.

That summer of COVID 2020 was a magical one with weekly trips with friends to Moonlight Beach where we walked, boogie boarded, and collected rocks.

In July 2021, I had surgery number 15 in the left eye to repair it. This was a collaborative effort by Team Shiley with Drs. Nudleman, Weinreb, and Afshari. Meanwhile, I passed my behind the wheel driving test (twice now) and the examiner said I was a very good driver!

Recently, I’ve had treatment for the retinal edema in my right eye with different drops and it’s getting better. My eyes are now stable and my newest challenge has been with other health issues—I had major back surgery in 2022.

Luckily, to this day, I continue with my normal activities of walking, swimming an hour each day, and golf. I’m hoping to do some traveling in the future! I am grateful to all the doctors and Team Shiley for helping me see!
The Shiley EyeMobile for Children at UC San Diego — a program in the Division of Community Ophthalmology at the Shiley Eye Institute (SEI) — provides free services to underserved, low-income students and it meets them in the neighborhoods where they live. The new EyeMobile replaces one that had been in service since 2008.

The EyeMobile services include eye exams by an optometrist, follow-up monitoring with teachers and parents, referral for subspecialist care as needed to the Anne F. and Abraham Ratner Children’s Eye Center at SEI and eyeglasses (if needed) – all at no cost to families. There is also bilingual parent and teacher information to teach families about the importance of eye/brain development and how eye care plays a crucial role in preparing children to learn.

“It’s estimated that 1 in 4 children have vision problems, making early detection and treatment very important,” said Robert N. Weinreb, MD, Director of the Shiley Eye Institute and Chair of the Viterbi Family Department of Ophthalmology. “This community service we have provided for over 20 years has proven to reduce the negative impact vision problems have on a child’s learning ability and development.”

The new EyeMobile is bigger and more efficient and was funded by an estate gift from a former patient of the SEI. It is a 33-foot-long recreational vehicle with two exam rooms and includes a TV in the waiting room to keep children occupied as they wait for their exams.

The program’s long-term goal is to provide eye care services to 20,000 low-income children each year. About 250 preschools are slated for visits from the EyeMobile this year in underserved areas all across San Diego County.

**Our program reached over 122 locations throughout San Diego County**

<table>
<thead>
<tr>
<th>2021 - 2022</th>
<th>2000 - 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children screened by autorefractor</td>
<td>8,277</td>
</tr>
<tr>
<td>Children received full dilated eye exams</td>
<td>1,020</td>
</tr>
<tr>
<td>Prescription glasses provided</td>
<td>895</td>
</tr>
<tr>
<td>High risk of vision conditions for subspecialty referrals</td>
<td>122</td>
</tr>
</tbody>
</table>
“The families we serve do not have another way to access eye exams. Some don’t even have transportation and others must decide between getting milk or getting eyeglasses for their kids,” said Iliana Molina, DHA, MBA, director of the UC San Diego Shiley EyeMobile for Children. Dr. Molina has been director of the EyeMobile for 15 years. She started out with the program as a student at UC San Diego in 2003 when the EyeMobile only had one exam room.

“My favorite part of the experience is delivering the eyeglasses to the students at school and watching their reaction when they can see clearly for the first time,” said Dr. Molina.

Since the program launched in 2001, the Shiley EyeMobile has screened more than 250,000 children across San Diego County—with close to 15,000 pairs of glasses provided in the last 20 years. Since the program began, more than 13,000 students’ vision has been screened annually. Before COVID-19, the Shiley EyeMobile traveled to 225 locations across San Diego County. In 2021-2022, the EyeMobile traveled 8,226 miles and delivered 895 pairs of prescription glasses to students.

The EyeMobile program is funded solely by foundations, corporations and individual donations. When funds have been raised, the former EyeMobile will be retrofitted to provide senior vision care services throughout San Diego County.
The PRPH2 Mutation Research Project was initiated during the past year under the scientific leadership of Radha Ayyagari, PhD and Shyamanga Borooah, MD, PhD. Funded by the Nixon Visions Foundation, led by philanthropists Janine and Brandon Nixon, the project studies the PRPH2 gene linked to macular dystrophy and boosts stem cell research, aimed at developing an early diagnosis and a cure. The Nixon Visions Foundation is also partnering with the Foundation Fighting Blindness to build momentum and increase global research in this area.

Macular dystrophy is a relatively rare eye condition affecting the central retina; it is not the same as macular degeneration which is more common. Macular dystrophy happens when mutations occur in the PRPH2 gene which damages the retina causing progressive sight loss and possibly blindness. Currently, there are no effective treatments to slow or stop the condition.

PRPH2 is a gene which provides instructions for making a protein (peripherin 2) in the retina that plays a role in normal vision. The retina is the light sensitive part of the back of the eye. This protein is necessary for full function of specialized cells within the retina called photoreceptors that detect light and color.

Drs. Ayyagari and Borooah are identifying patients with the PRPH2 mutation for genetic evaluation, imaging and assessment for changes over time as well as testing novel treatments for the mutation using stem cell models.

There already have been several developments including:

- Assembling a worldwide team of investigators each with a significant collection (50-200) of patients carrying a spectrum of PRPH2 mutations.
- Identifying a set of clinically relevant PRPH2 mutations for phenotype-genotype association analysis.
- Generating stem cells that carry the c.623G>A mutation.
- Coming close to completion of the differentiation to retinal pigment epithelial cells as well as starting differentiation of retinal organoids (mini-retina).
• Introduction of the c.623G>A mutation into a lab animal genome with plans for offspring to have their DNA analyzed.

Working with a global team of investigators and a cohort of patients from the United States, the United Kingdom, Southeast Asia and Europe, research is being conducted to analyze phenotype-genotype association.

Genotype is a person’s unique DNA sequence; phenotype is a person’s genes combined with environmental factors. The research team is attempting to elucidate how an individual’s genetics (genotype) and their characteristics from the interaction of genetics and environment (phenotype) cause the genes’ mutation and the degeneration of the retina in this particular type of macular dystrophy. They also are evaluating if machine learning tools can be used for the classification of PRPH2 gene and studying the phenotype-genotype association using artificial intelligence (AI).

Cell differentiation happens when a cell undergoes changes to become a more specific type of cell. For this research, differentiation to retinal organoids—the three-dimensional cell cultures created by stem cells—has begun. Tests will be run on the cell cultures created specifically aimed at the c.623 G>A PRPH2 mutation.

Dr. Borooah’s team has designed a CRISPR-Cas9 gene editing treatment for the c.623 G>A PRPH2 mutation which has been tested; it will be used to target and cut the mutation in the DNA. The next step is to test the CRISPR gene editing on the stem cell produced genes if the cutting strategy on the normal DNA is safe.

Research also is being done to evaluate personalized treatments by using cell cultures and the animal models with PRPH2 mutations.
Using stem cell technologies, Jiun Do, MD, PhD, Assistant Professor, is investigating potential treatments for glaucoma that regenerates the optic nerve and restore the connections between the eye and the brain. These connections are lost in glaucoma and many other eye diseases, resulting in permanent vision loss. He is developing methods to directly replace the cells that are lost from eye diseases. The process starts by genetically manipulating and optimizing stem cells for transplantation then transferring the modified stem cells into the appropriate location within the eye using novel intraocular techniques.

Additionally, Dr. Do is pioneering the development of “neuronal relays” to reconnect the injured optic nerve to the brain. By adapting this stem cell strategy to the optic nerve, it may be possible to successfully transplant a whole eye. Ultimately, these research directions aim to provide new directions for vision restorative therapies.
Developing Treatments for Inherited Retinal Disease

Shyamanga Borooah, MD, PhD, Assistant Professor, and his team are developing novel therapies for a number of inherited retinal diseases using a variety of disease specific treatment approaches. The treatments include gene therapy and CRISPR based gene editing. The lab's main focus is macular degeneration, including late-onset retinal degeneration, Sorsby fundus dystrophy, dominant drusen, and more recently pattern dystrophy, one of the most common inherited retinal diseases. These are all sight threatening diseases.

His team has generated patient stem cells carrying the disease-causing mutations and are converting these cells to either retinal cells or organoids (mini-eyes) to enable disease modeling in a dish. The lab's main focus is macular degeneration, including late-onset retinal degeneration, Sorsby fundus dystrophy, dominant drusen, and more recently pattern dystrophy, one of the most common inherited retinal diseases. These are all sight threatening diseases.

His team has generated patient stem cells carrying the disease-causing mutations and are converting these cells to either retinal cells or organoids (mini-eyes) to enable disease modeling in a dish. The lab's main focus is macular degeneration, including late-onset retinal degeneration, Sorsby fundus dystrophy, dominant drusen, and more recently pattern dystrophy, one of the most common inherited retinal diseases. These are all sight threatening diseases.

Developing Treatments for Inherited Retinal Disease

Researchers under the supervision of Karl Wahlin, PhD, Assistant Professor and Director of the Richard C. Atkinson Laboratory for Regenerative Ophthalmology, are developing novel strategies to regenerate new optic nerve and photoreceptor cells within the eye. Many species, including fish, can regrow damaged cells within the eye after injury. While humans seem to have lost this capability, Dr. Wahlin and his team believe that this process is merely dormant and can be activated in the human eye too. A main limitation to restoring vision in humans is our inability to grow new cells that are lost during disease. One approach that might solve this is to regenerate new cells by activating genes that control normal eye development, as well as what is active during eye regeneration in other species. In several publications this year, the Wahlin lab demonstrated that human retinas express many of the same genes expressed in other species, particularly with respect to regulatory genes controlling cell type formation. Some of these control vast gene programs that control cell fate, such as those in the optic nerve, to retinal pigmented cells in glaucoma. In fact, these new cellular tools have already been used to explore and identify neuroprotective drugs that help optic nerve cells survive injury. A similar approach is under development for creating new light-sensing photoreceptor cells that could lead to exciting new ways to study and reverse permanent vision loss from glaucoma. In fact, these new cellular tools have already been used to explore and identify neuroprotective drugs that help optic nerve cells survive injury. A similar approach is under development for creating new light-sensing photoreceptor cells that could lead to exciting new ways to study and reverse permanent vision loss from glaucoma. In fact, these new cellular tools have already been used to explore and identify neuroprotective drugs that help optic nerve cells survive injury. A similar approach is under development for creating new light-sensing photoreceptor cells that could lead to exciting new ways to study and reverse permanent vision loss from glaucoma.

To prove that these genes were important, the team devised a series of experiments with new human optic nerve cells in record time. The ability to generate new optic nerve cells could lead to exciting new ways to study and reverse permanent vision loss from glaucoma. In fact, these new cellular tools have already been used to explore and identify neuroprotective drugs that help optic nerve cells survive injury. A similar approach is under development for creating new light-sensing photoreceptor cells that could lead to exciting new ways to study and reverse permanent vision loss from glaucoma. In fact, these new cellular tools have already been used to explore and identify neuroprotective drugs that help optic nerve cells survive injury. A similar approach is under development for creating new light-sensing photoreceptor cells that could lead to exciting new ways to study and reverse permanent vision loss from glaucoma.
The Shiley Eye Institute (SEI) received an innovative donation to establish the Downtown San Diego Lions Club BioBank for Vision in 2017. Conceived in 2006 by Robert N. Weinreb, MD, the BioBank was launched in 2012. The BioBank stores a library of biological samples with personal history that scientists can use to investigate predictors for diseases and effectiveness of therapies. Under the direction of Radha Ayyagari, PhD, and Linda Zangwill, PhD, these biological samples have been utilized to (1) learn about predictors of diseases (biomarkers); (2) determine effectiveness or lack of effectiveness of therapies; (3) understand disease pathologies; and (4) develop successful cures for blinding eye diseases.

Demographic, ethnic, medical and risk factor history data are collected from qualified patients in the SEI clinic. The details of sample collection, processing, analysis and exact freezer storage location of samples are recorded in the BioBank database system. Each step of the process ensures that all patient data and samples are stored, tracked and readily available to share with investigators, along with all linked clinical, demographic, genotype, and phenotype information while maintaining strict confidentiality. This process has been approved by the UCSD Institutional Review Board Committee and involves all activities including the sample collection, sample processing and intended use and handling protocol.

Patients with inherited eye diseases who participate in this research have provided blood samples that are processed into DNA, RNA and other important components of blood. These samples are isolated, quantified and standardized in preparation for future genetic analysis. Moreover, induced pluripotent stem cells from specific individuals also are stored in the BioBank.

This year Biobank initiated partnership with one of only 4 National Institutes of Health (NIH) Bridge to Artificial Intelligence (Bridge2AI) data generation projects. The NIH’s Bridge2AI project is intended to speed up the widespread use of AI in biomedical research and health care by providing public access to ethically sourced data repositories. The UCSD data generation project called AI-READI (AI Ready and Equitable Atlas for Diabetes Insights), will provide public data sets to learn how diabetes is influenced by patients’ genes, lifestyle and environment. The Downtown San Diego Lions Club biobank will provide the infrastructure for the AI-READI biospecimen repository at UCSD. The Downtown San Diego Lions Club BioBank for Vision is an invaluable resource for SEI investigators that contributes towards the future of finding cures for blinding eye diseases helping patients globally.
How can we conceive of going to the moon, traveling to Mars, or undertaking long-haul space travel if we can’t see? These are the challenges facing humans with the goal of exploring the next frontier of space. Spaceflight Associated Neuro-ocular Syndrome (SANS) is an eye problem where the nerve of the eye (optic nerve) swells and bleeding occurs in the retina because many of the cells in the eye die. Today, SANS is a leading healthcare priority for astronauts and is under intense study.

The Shiley Eye Institute has contributed to this research for nearly a decade. In the last few years, lead investigator, Alex Huang, MD, PhD, Associate Professor and Alfred Vogt Chair in Ophthalmology, has worked with NASA to study changes to the eyes that can occur on the International Space Station (ISS). Today, results from astronaut eye exams on the ISS are sent to SEI and studied to uncover the cause of SANS. Attempts to develop countermeasures are underway in a unique international collaboration.

In a multinational study, NASA and Deutsches Zentrum fur Luft- und Raumfahrt (DLR – the German Aerospace Center) developed a special model to mimic what happens to astronauts in space. Human subjects lay down in a bedrest study with their heads lower than their feet by 6 degrees. This mimics the lack of gravity on the ISS where total body fluid in our lower extremities redistribute to our heads. This fluid shift is believed to be the cause of SANS.

Potential countermeasures to this fluid shift, such as exercise or lower body chambers that use negative pressure to hold the fluid in the legs, are being studied in this bedrest model. The challenge becomes: how to study the eye in such a unique position where subjects are lying down! Eye exams on earth are performed with patients sitting upright in a diagnostic device in a clinic.

Dr. Huang is leading an international team at the :envihab in Cologne, Germany, to understand the effects of bedrest positioning on the eye and the potential of SANS countermeasures. Dr. Huang and NASA investigators worked with German aerospace scientific collaborators on how best to study the eye in the unique bedrest model. This included functional electrophysiological tests of the retina and optic nerve. Diagnostic equipment was re-engineered followed by testing and validation by team members.

Now, with these tools in place, if any countermeasure proves effective in protecting vision in the bedrest studies, imminent deployment to the ISS can occur. Ultimately, protecting the eye will allow humans to safely explore, experience, and travel to space for longer periods of time. Dr. Huang’s SANS investigations may also illuminate the causes and treatments for earthly eye diseases such as glaucoma optic neuropathy.
The African Descent and Glaucoma Evaluation Study (ADAGES) began over 20 years ago with researchers from the Hamilton Glaucoma Center at the Viterbi Family Department of Ophthalmology at UC San Diego, the Edward S. Harkness Eye Institute at Columbia University Irving Medical Center, and the Department of Ophthalmology at University of Alabama-Birmingham. The latest findings from the team show that the Black race group and the White race group had similar rates of visual field progression (loss of two or more lines of vision) despite the disease being more aggressive in the Black race group.

Robert N. Weinreb, MD, Director of the Shiley Eye Institute (SEI) and Chair of the Viterbi Family Department of Ophthalmology, and Linda Zangwill, PhD, Professor of Ophthalmology, led the team of researchers. The Hamilton Glaucoma Center, under Dr. Zangwill’s direction, was the data coordinating center for the research. The average follow-up time with participants was 11 years.

“We know African Americans over the age of 40 are at a higher risk for glaucoma,” said Dr. Weinreb. “This makes it important for us to investigate whether there are any differences between African Americans with glaucoma versus their white counterparts from diagnosis to progression.”

Dr. Zangwill, as Director of the Imaging Data Evaluation and Analysis (IDEA) Center at the Hamilton Glaucoma Center said, “Gathering and analyzing this data over time has had some surprising revelations. Our data showed that when African American patients have equal access to care, the progression of glaucoma between them and white patients are not as significant as they were in past studies.”

The research was begun in order to find what may cause differences in glaucoma onset and rate of progression between Black and White race participants. Participants had to have primary open angle glaucoma (POAG).

The researchers believe the age difference in this study has significant clinical implications, because a larger number of the Black race participants were diagnosed with glaucoma at a younger age and may develop visual impairment in their lifetimes.
Christopher Girkin, MD, MSPH, Professor of Ophthalmology at the University of Alabama-Birmingham, who was a glaucoma fellow at UC San Diego when the study began, stated “It’s been a rewarding 20-year collaboration with Drs. Weinreb and Zangwill working on this research. Much of my career has been focused on studying the mechanism behind the racial disparity in glaucoma and methods to reduce this disparate burden.”

Previous population-based studies showed that Black race participants had higher prevalence and more rapid progression of glaucoma. Researchers surmise that their findings in this study are different from the prior studies because previously Black participants were adversely affected due to socioeconomic disparities and differences in access to treatment. In this current research, the findings show the rates of visual field progression were similar. This means that with improved access to medication, more frequent visual field testing, and better adherence to office visits through phone calls, patients will have better health outcomes.

Natalie A. Afshari, MD, Professor of Ophthalmology, and her team have been investigating how to improve the ocular surface of the cornea to treat dry eye and other conditions. In collaboration with Helen Makarenkova, PhD (Scripps Research) they studied how fibroblast growth factor 10 (FGF10) could help maintain and regenerate the eye’s corneal epithelium and ocular surface. FGF10 is a protein made by white blood cells and is critical to normal cellular development.


Those mouse models and human tissue showed that FGF10 promoted cellular regeneration in adult lacrimal glands. The team believes the findings have future therapeutic utility for dry eye diseases by harnessing the regenerative potential of the cornea and lacrimal gland.

In her ocular surface investigations, Dr. Afshari also characterized the effects of three anti-inflammatory eye drops on the ocular surface corneal epithelial cells in-vitro to better understand and treat dry eye syndrome (DES).


These experiments demonstrated that of the eye drops tested, tacrolimus enhanced cell survival while cyclosporine (Restasis) offered a protective effect against cell death.

Immunostaining of lacrimal gland cells showing that FGF 10 treatment increased proliferation rates compared to controls.
Smoking Effects in Glaucoma

“Healthy life, healthy body, healthy optic nerve”

According to the Centers for Disease Control and Prevention (CDC), smoking cigarettes increases one’s risk for coronary heart disease by 2 to 4 times; for stroke by 2 to 4 times; for men developing lung cancer by 25 times; and for women developing lung cancer by almost 26 times.

Those effects of smoking may be well known and understood. What has not been explored in as much depth until recently is how smoking affects a person’s eyes and vision. Researchers at medical schools across the country have been investigating the effects of smoking on eyes and their findings show that smoking does adversely affect one’s eyesight.

Sasan Moghimi, MD, Associate Professor of Ophthalmology at UC San Diego’s Shiley Eye Institute and Viterbi Family Department of Ophthalmology, has been working on this research along with Robert N. Weinreb, MD, Sally Baxter, MD, MSc, and Linda Zangwill, PhD.

The research spanned a couple of glaucoma studies conducted by the Hamilton Glaucoma Center at SEI with the Edward S. Harkness Eye Institute at Columbia University Medical Center and the Bernard School of Medicine at the University of Alabama-Birmingham.

In one of their reports, started in 2020 and published in the Academy of Ophthalmology’s (AAO) Ophthalmology magazine, patients with primary open angle glaucoma (POAG) were followed for over three years with at least 5 visual field (VF) tests and 5 visits of optical coherence tomography (OCT). OCT is an imaging test of the eye using light waves to take cross-section pictures of the retina. The findings showed that smokers’ eyes had VF progression 2.2 times more than non-smokers’—meaning the smokers’ glaucoma worsened.

It was also discovered that the more someone smoked, there was reduced optic nerve vessel density in glaucoma and more susceptible to glaucoma.
Aging Effects on the Eyes

Robert N. Weinreb, MD, Chair and Distinguished Professor of Ophthalmology and Won-Kyu Ju, PhD, Professor of Ophthalmology, at the Shiley Eye Institute and Viterbi Family Department of Ophthalmology collaborated on research which shows that repetitive stress in retinal tissue accelerates aging of the eye. The study was first authored by Dorota Skowronska-Krawczyk, MSc, PhD, Assistant Professor, Physiology & Biophysics and Ophthalmology and faculty of the Center for Translational Vision Research at the UC Irvine School of Medicine. Dr. Skowronska-Krawczyk completed her post-doctoral fellowship at UC San Diego’s Shiley Eye Institute from 2006-2010 and then was on the SEI staff.


The team’s research shows how fluctuations in eye pressure affects retinal tissue, creating epigenetic (how cells control gene activity without changing DNA) changes such as one would find with natural aging.

“Compared with young mice, our histological data clearly showed the evidence of a significant sectorial loss of axons in the optic nerve head and epigenetic changes in the retina of elevated IOP-induced aged mice, guiding us to develop potential therapeutic strategies to prevent progressive loss of RGCs, axons and vision in aging and glaucomatous neurodegeneration,” stated Dr. Ju.

“The research clearly shows that smoking damages a person’s vision. When someone stops smoking, they help their overall health and may help their sight,” stated Dr. Moghimi.

Interestingly, they demonstrated that after ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. This is in line with previous studies that demonstrated the risk of age-related macular degeneration (AMD) reduces to a baseline 20 years after smoking cessation.

Further studies are needed to see if the smoker stops smoking whether this will decrease the glaucoma progression.

progression. In addition, their other reports showed that heavy smokers had faster rates of thinning of their retinal nerve fiber layer (RNFL). The RNFL is made primarily of ganglion cells, which are the retinal neurons that communicate directly with the brain.
SEI is committed to supporting the well-being of our clinical and research faculty, residents, fellows and staff. They work long hours spending most of their time on their feet attending to patients, operating in surgery or researching in the laboratories.

Spearheading this initiative at SEI are Wellness Program Directors Catherine Y. Liu, MD, PhD and David Granet, MD, who are collaborating with the UC San Diego Health Physician Wellness Office, the UC San Diego Health Employee Wellbeing Program and Integrative Medicine.

Drs. Granet and Liu are implementing UC San Diego initiatives supporting the faculty and staff’s overall wellbeing. The faculty part of the initiative will focus on physician’s mental health, practice efficiency, family care, academic engagements, and personal finances. Additionally, they have tasked the IT division to find a systems-based offering which may help improve clinic efficiency for our providers.

“We are very interested in ways to optimize the professional fulfillment of our extraordinary faculty,” said Dr. Liu, who pointed out that the faculty’s wellness is key to SEI providing effective health care to our community.

With this goal in mind, there are plans for more sporting events like the recent table tennis tournament. Plans are underway for Healthy Lunch and Learn workshops focusing on nutrition, workplace movement, and mindfulness for all faculty and staff. SEI’s Wellness Directors are focused on activities which will foster personal resilience and health and contribute to positive team building. They had help from Robert N. Weinreb, MD, Don Kikkawa, MD, Craig Kishaba, MBA and Karen Anisko Ryan’s team.
The promotion of mental health and creating connection between our diverse staff and faculty have always been key priorities for the UC San Diego Shiley Eye Institute and Viterbi Family Department of Ophthalmology.

This year we combined these efforts in a department ping pong tournament. Participants included the faculty, residents, fellows, researchers, nurses, and staff, across all departmental specialty sub-divisions such as glaucoma, cornea, retina, optometry, administration, and the operating room.

The laughs, cheering, and even competitiveness that were present during the tournament created a unique opportunity for department staff and faculty who would normally not interact with one another, a space to form connection, camaraderie, and boost morale.
Every year, Shiley Eye Institute specialists are honored to be named as being “the best” by major national and local organizations.

**Sally L. Baxter, MD, MSc**, Assistant Professor of Ophthalmology, was voted to the periodical Ophthalmology Management’s inaugural “40 Under 40” list for achieving excellence in ophthalmology as the next generation.

**Napoleone Ferrara, MD**, Distinguished Professor of Ophthalmology and Pathology, received the Pair Prize for American-Italian Relations from the Centro Studi Americani in Rome, Italy, October 2021. He was also awarded the XIII Weinman Award from the Barry and Virginia Weinman Innovation Fund in Honolulu, HI, January 2022.

**Alex A. Huang, MD, PhD**, Associate Professor of Ophthalmology, received the Roche Collaborative Research Fellowship Award with Dr. Shikha Gupta as mentee. He was also awarded the Top Poster Designation at the 2022 American Glaucoma Society.

**Don O. Kikkawa, MD**, Distinguished Professor of Clinical Ophthalmology and Plastic Surgery, received the 2022 UW-Madison Ophthalmology Alumni Association’s Distinguished Alumni Award.

**Jeffrey Lee, MD**, Associate Professor, and **Robert N. Weinreb, MD**, Distinguished Professor of Ophthalmology and Bioengineering, were named to Newsweek’s “America’s Best Doctors 2022”.

**Shira L. Robbins, MD**, Professor of Ophthalmology, was elected Vice President Medical Staff UC San Diego Health System and is now Vice Chair, Medical Staff Professionalism Committee.

**Robert N. Weinreb, MD**, Distinguished Professor of Ophthalmology and Bioengineering, was recognized as one of the “Top 10 in the World” as Most Influential in Ophthalmology on the THE POWER LIST 2022 by The Ophthalmologist international periodical. He was also nominated as a GLAUCOMA VISIONARY by the periodical Glaucoma Today.

**TRAINEES**

Richard L. Scawn, MBBS (Oculoplastics Visiting Scholar, 2014) received the 2022 American Academy of Ophthalmology Achievement Award for his contributions made to the Academy, its scientific and educational programs and to ophthalmology.

Michele Ting, MD (Oculoplastics Fellow, 2022) received the American Society of Ophthalmic Plastic and Reconstructive Surgery Research award 2022 for her paper titled, “A Comparison of Proptosis Reduction with Teprotumumab vs Surgical Decompression Based on Fat-to-Muscle Ratio in Thyroid Eye Disease”

Ben Xu, MD, PhD (Glaucoma Fellow, 2017) was named to Newsweek’s “America’s Best Doctors 2022”.

---

**Congratulations**
SEI BY THE NUMBERS 2022

**Patient Visits**
- 2020: 110,454
- 2021: 125,532
- 2022: 140,812

**Surgical Procedures**
- 2020: 4,482
- 2021: 6,427
- 2022: 8,126

**Publications**
- Glaucoma: 106
- Oculoplastics: 26
- Retina: 25
- Pediatric Ophthalmology: 16
- Cornea: 11
- Other: 13
- Informatics: 7

**Other Statistics**
- 204,723 Phone Calls
- 5,432 Same Day Appointments
- 204 Publications
- 65 Grants
- 35 Clinical Trials
Robert N. Weinreb, MD
Chair & Distinguished Professor, Department of Ophthalmology
Director, Shiley Eye Institute
Director, Hamilton Glaucoma Center
Distinguished Professor of Bioengineering
Morris Gleich, MD Chair in Glaucoma

GLAUCOMA
Dr. Weinreb specializes in glaucoma surgery (conventional and minimally invasive), medical management of glaucoma; cell and molecular biology of aqueous outflow; mechanisms of optic nerve damage in glaucoma; visual function; neuroprotection in glaucoma; drug delivery to eye; cataract surgery.

Natalie A. Afshari, MD, FACS
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley

CORNEA & REFRACTIVE
Dr. Afshari specializes in Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.

Radha Ayyagari, PhD
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of Downtown San Diego Lions Club BioBank for Vision
Viterbi Family Chair of Ophthalmic Genetics

GENETICS
Dr. Ayyagari specializes in molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.

Dirk-Uwe Bartsch, PhD
Adjunct Professor of Ophthalmology

RETINA & VITREOUS
Dr. Bartsch specializes in retinal imaging; scanning laser imaging-confocal/non-confocal; optical coherence tomography (OCT); indocyanine green and fluorescein angiography; tomographic reconstruction of the posterior pole.
Sally L. Baxter, MD, MSc
Assistant Professor of Ophthalmology
Chief, Division of Ophthalmology Informatics and Data Science

COMPREHENSIVE OPHTHALMOLOGY
Dr. Baxter specializes in comprehensive ophthalmology; cataract surgery; diabetic retinopathy screening; caring for underserved populations; digital health and informatics and data science.

Akram Belghith, PhD
Assistant Project Scientist of Ophthalmology
GLAUCOMA
Dr. Belghith specializes in change detection and monitoring of glaucoma; image processing and machine learning classifier analyses.

Shyamanga Borooah, MBBS, MRCP (UK), MRCSEd, FRCOphth, PhD
Assistant Professor of Clinical Ophthalmology
RETINA & VITREOUS
Dr. Borooah specializes in adult and childhood inherited retinal degenerations; age-related macular degeneration; retinal vein occlusion; central serous retinopathy and diabetic eye disease.

Christopher Bowd, PhD
Research Scientist of Ophthalmology
Director of the Hamilton Glaucoma Center-based Visual Field Assessment Center
Co-Director of the Hamilton Glaucoma Center-based Imaging Data Evaluation and Analysis (IDEA) Center

GLAUCOMA
Dr. Bowd specializes in early detection and monitoring of glaucoma; machine learning classifier analyses of imaging and visual function measurements.
Stuart I. Brown, MD
Professor of Ophthalmology, Emeritus
CORNEA & REFRACTIVE
Dr. Brown specializes in corneal transplantations and cataract surgeries.

Andrew S. Camp, MD
Assistant Professor of Ophthalmology
Acting Chief of the Ophthalmology Section at the Veterans Administration Medical Center
GLAUCOMA
Dr. Camp specializes in adult and pediatric glaucoma.

Mark Christopher, PhD
Assistant Project Scientist of Ophthalmology
GLAUCOMA
Dr. Christopher specializes in deep learning applications in imaging and visual function in glaucoma.

Jiun Do, MD, PhD
Assistant Professor of Ophthalmology
GLAUCOMA
Dr. Do specializes in translational research; retinal and optic nerve regeneration; retinal ganglion cell replacement for glaucoma and other optic neuropathies; optic nerve relays; patient measured intraocular pressures and glaucoma progression.
Napoleone Ferrara, MD  
Distinguished Professor of Ophthalmology and Pathology  
Senior Deputy Director for Basic Sciences, UC San Diego Moores Cancer Center  
Ben and Wanda Hildyard Chair for Diseases of the Eye  
**RETINAL VASCULAR**  
Dr. Ferrara specializes in regulation of angiogenesis (the formation of new blood vessels) and the role of VEGF (vascular endothelial growth factor); continues to develop new therapies to treat age related macular degeneration building upon past development of Avastin® and Lucentis®.

Henry A. Ferreyra, MD  
Clinical Professor of Ophthalmology  
**RETINA & VITREOUS**  
Dr. Ferreyra specializes in electrophysiology inherited disorders of the retina; age-related macular degeneration; diabetic retinopathy; retinopathy of prematurity.

William R. Freeman, MD  
Distinguished Professor of Ophthalmology  
Vice Chair, Department of Ophthalmology  
Director, Jacobs Retina Center  
Co-Director, Retina Division  
**RETINA & VITREOUS**  
Dr. Freeman specializes in retinal detachment; diabetic retinopathy; macular holes & age-related macular degeneration.

Michael H. Goldbaum, MD  
Professor of Ophthalmology in Residence, Emeritus  
**RETINA & VITREOUS**  
Dr. Goldbaum specializes in surgical and medical treatment of the retina and vitreous; macular degeneration; pediatric retina; ocular tumors; glaucoma informatics.
David B. Granet, MD, MHCM, FACS, FAAO, FAAP

Professor of Clinical Ophthalmology and Pediatrics
Vice Chair, Department of Ophthalmology
Anne Ratner Chair of Pediatric Ophthalmology
Director, Anne F. & Abraham Ratner Children’s Eye Center
Director, Division of Pediatric Ophthalmology & Eye Alignment

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Dr. Granet specializes in pediatric ophthalmology and strabismus, adult eye movement problems, strabismus surgery, childhood eye misalignments & disorders, and nystagmus.

Weldon W. Haw, MD
Clinical Professor of Ophthalmology
CORNEA & REFRACTIVE
Dr. Haw specializes in cataract surgery; dry eye/pterygium; cornea transplantation; refractive surgery/LASIK.

Chris W. Heichel, MD, FACS
Clinical Professor of Ophthalmology
CORNEA & REFRACTIVE
Dr. Heichel specializes in corneal transplantations and keratoprosthesis; challenging cataract and IOL surgeries; LASIK, Intacs, and Visian ICL advanced techniques in laser and refractive surgery; keratoconus ocular surface tumors; limbal stem cell transplantation.

Alex A. Huang, MD, PhD
Associate Professor of Ophthalmology
Alfred Vogt Chair in Ophthalmology
GLAUCOMA
Dr. Huang specializes in glaucoma, cataracts, and ocular changes during space flight.

David B. Granet, MD, MHCM, FACS, FAAO, FAAP

Professor of Clinical Ophthalmology and Pediatrics
Vice Chair, Department of Ophthalmology
Anne Ratner Chair of Pediatric Ophthalmology
Director, Anne F. & Abraham Ratner Children’s Eye Center
Director, Division of Pediatric Ophthalmology & Eye Alignment

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Dr. Granet specializes in pediatric ophthalmology and strabismus, adult eye movement problems, strabismus surgery, childhood eye misalignments & disorders, and nystagmus.

Weldon W. Haw, MD
Clinical Professor of Ophthalmology
CORNEA & REFRACTIVE
Dr. Haw specializes in cataract surgery; dry eye/pterygium; cornea transplantation; refractive surgery/LASIK.

Chris W. Heichel, MD, FACS
Clinical Professor of Ophthalmology
CORNEA & REFRACTIVE
Dr. Heichel specializes in corneal transplantations and keratoprosthesis; challenging cataract and IOL surgeries; LASIK, Intacs, and Visian ICL advanced techniques in laser and refractive surgery; keratoconus ocular surface tumors; limbal stem cell transplantation.

Alex A. Huang, MD, PhD
Associate Professor of Ophthalmology
Alfred Vogt Chair in Ophthalmology
GLAUCOMA
Dr. Huang specializes in glaucoma, cataracts, and ocular changes during space flight.
Won-Kyu “Daniel” Ju, PhD  
Professor of Ophthalmology and Bioengineering  

GLAUCOMA  
Dr. Ju specializes in cellular and molecular mechanisms for neurodegeneration; neuro-inflammation, and neuro-protection in glaucoma and Alzheimer’s disease; characterization of melanopsin-expressing retinal ganglion cell-mediated multiscale connectome in Alzheimer’s disease.

Don O. Kikkawa, MD, FACS  
Distinguished Professor of Clinical Ophthalmology and Plastic Surgery  
Vice Chair for Clinical Services, Department of Ophthalmology  
Chief, Division of Oculofacial Plastic and Reconstructive Surgery  

Dr. Trude Kahn Hollander Chair in Ophthalmology  

NEURO-OPHTHALMOLOGY  
Dr. Kline specializes in optic nerve disease; double vision; pupillary disorders; demyelinating diseases; visual abnormalities accompanying stroke.

Lanning Kline, MD  
Clinical Professor of Ophthalmology  

Bobby S. Korn, MD, PhD, FACS  
Professor of Clinical Ophthalmology and Plastic Surgery  

OPHTHALMIC PLASTIC & RECONSTRUCTIVE SURGERY  
Dr. Korn specializes in cosmetic and reconstructive surgery; blepharoplasty; ptosis surgery; congenital birth defects; endoscopic forehead lifting; thyroid eye disease management; optic nerve sheath fenestration/decompression; eyelid and orbital tumors and cancers; lacrimal/tear outflow system disorders; bulging or proptosis of eyes; reconstruction of eyelids post cancer removal; reconstruction after trauma/eye injuries; facial fillers and skin rejuvenation.
Jeffrey E. Lee, MD
Associate Clinical Professor of Ophthalmology
Program Director, Ophthalmology Residency

John H. K. Liu, PhD
Professor of Ophthalmology
Director, Glaucoma Sleep Laboratory

Catherine Y. Liu, MD, PhD
Assistant Professor of Clinical Ophthalmology

Sasan Moghimi, MD
Associate Professor of Ophthalmology

Dr. Liu specializes in ptosis surgery; blepharoplasty; lacrimal disease and surgery; eyelid and orbital oncology; blepharospasm and hemifacial spasm; orbital fractures; cranio-facial disorders involving the eyelid and orbit; pediatric oculoplastics; surgical and non-surgical facial rejuvenation.

Dr. Moghimi specializes in imaging in early detection and monitoring of the disease; angle-closure glaucoma diagnosis and treatment.
Mansoor Movaghhar, MD
Associate Clinical Professor of Ophthalmology

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Dr. Movaghhar specializes in strabismus/eye misalignment/ double vision; adult eye movement problems; amblyopia; pediatric cataracts; nasolacrimal duct disorders; congenital eye syndromes; systemic diseases affecting the eyes.

Thao P. Nguyen, MD
Assistant Clinical Professor of Ophthalmology

COMPREHENSIVE OPHTHALMOLOGY
Dr. Nguyen specializes in cornea; anterior segment and cataract surgery.

Eric Nudleman, MD, PhD
Associate Professor of Clinical Ophthalmology
Co-Director, Retina Division
Viterbi Family Chair for Retinal Vascular Diseases

RETINA & VITREOUS
Dr. Nudleman specializes in adult & pediatric vitreoretinal diseases, including AMD, diabetic eye disease; retinal vein occlusions; retinal detachments; proliferative vitreoretinopathy, macular holes & epiretinal membranes; pediatric vitreoretinal diseases, retinopathy of prematurity, familial exudative vitreoretinopathy, Coats disease, fetal vascular syndrome, & intraocular trauma. developmental angiogenesis.

Manuel Puig-Llano, MD, FACS, FASRS
Clinical Professor of Ophthalmology

COMPREHENSIVE OPHTHALMOLOGY
Professor of Ophthalmology & Neurosciences

Dr. Savino specializes in myasthenia gravis; optic neuritis; atrophy and neuropathy of brain and nervous system; tumors; visual field defects; degenerative, metabolic, inflammatory and demyelinating diseases; vascular disorders.

Peter J. Savino, MD
Assistant Professor of Clinical Ophthalmology
Division Chief, Ocular Oncology
Associate Member, Solid Tumor Therapeutics
UC San Diego Health Moores Cancer Center

Ocular Oncology
Dr. Savino specializes in myasthenia gravis; optic neuritis; atrophy and neuropathy of brain and nervous system; tumors; visual field defects; degenerative, metabolic, inflammatory and demyelinating diseases; vascular disorders.

Shira L. Robbins, MD, FAAO, FAAP
Professor of Clinical Ophthalmology
Educational Director of Pediatric Ophthalmology/Strabismus Division
Vice President Medical Staff for UC San Diego Health

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Dr. Robbins specializes in strabismus; eye misalignment; double vision; amblyopia; retinopathy of prematurity; pediatric glaucoma and cataracts; including intraocular lens placement; nasolacrimal duct disorders; congenital eye syndromes; craniofacial syndromes; systemic diseases affecting the eyes; nystagmus.

Jolene Rudell, MD, PhD
Assistant Professor of Clinical Ophthalmology

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Dr. Rudell specializes in strabismus; eye misalignment; double vision; amblyopia; pediatric cataracts; nasolacrimal duct disorders; congenital eye syndromes; systemic diseases affecting the eyes.

Nathan L. Scott, MD, MPP
Assistant Professor of Clinical Ophthalmology
Division Chief, Ocular Oncology
Associate Member, Solid Tumor Therapeutics
UC San Diego Health Moores Cancer Center

OCULAR ONCOLOGY
Dr. Scott specializes in ocular oncology; uveal melanoma; retinoblastoma; choroidal melanoma; ocular surface tumors (OSSN, conjunctival melanoma, lymphoma, etc.); ocular trauma; complicated retinal detachment; proliferative vitreoretinopathy; diabetic retinopathy; macular hole; age-related macular degeneration; retinal vascular occlusive disease; epiretinal membranes.
Peter Shaw, PhD
Associate Adjunct Professor of Ophthalmology

RETINA & VITREOUS
Dr. Shaw investigates how genetic and oxidative stress risk factors impact ocular disease; development of molecular and gene therapy methods to treat eye diseases.

Doran B. Spencer, MD, PhD
Assistant Clinical Professor of Ophthalmology

UVEITIS
Dr. Spencer specializes in uveitis and ocular inflammation.

Christopher B. Toomey, MD, PhD
Assistant Professor of Clinical Ophthalmology

RETINA & VITREOUS
Dr. Toomey specializes in retina and vitreous; adult vitreoretinal disease, with specialization in age-related macular degeneration (AMD); diabetic retinopathy; retinal vein occlusions; retinal detachments; proliferative vitreoretinopathy; macular holes; and epiretinal membranes. Scientific interest in age-related macular degeneration with a focus on the early and intermediate “dry” stages of AMD.

Cristiana Vasile, MD, MAS
Associate Clinical Professor of Ophthalmology

GLAUCOMA
Dr. Vasile specializes in glaucoma management, and clinical research in glaucoma and optic nerve assessment.
Karl Wahlin, PhD
Assistant Professor of Ophthalmology
Director, Richard C. Atkinson Laboratory for Regenerative Ophthalmology

**REGENERATIVE OPHTHALMOLOGY**
Dr. Wahlin specializes in directed differentiation of pluripotent stem cells and their application towards the study of retinal development and eye disease; photoreceptor cell development and retinal connectivity; retinal and optic nerve regeneration.

Derek S. Welsbie, MD, PhD
Associate Professor of Ophthalmology

**GLAUCOMA**
Dr. Welsbie specializes in neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Linda M. Zangwill, PhD
Professor of Ophthalmology
Interim Director, Research

**Director, Hamilton Glaucoma Center, Data Coordinating Center**

Richard K. Lansche, MD & Tatiana A. Lansche Chair in Ophthalmology

**GLAUCOMA**
Dr. Zangwill specializes in the relationship between structural & functional change in the aging & glaucoma eye; developing computational & statistical techniques to improve glaucomatous change detection, reduce the number of visits & optimize the type of testing required; identify risk factors that can predict glaucomatous progression & rapidly progressing glaucoma.
Optometry & Low Vision

John F. Kulischak, OD
OPTOMETRY SUPERVISOR

OPTOMETRY SCHOOL
University of California Berkeley

RESIDENCY
Palo Alto VA Medical Center

Maria Laura Gomez, MD, OD

OPTOMETRY SCHOOL
Southern California College of Optometry at Marshall B. Ketchum University

MEDICAL SCHOOL & RESIDENCY
Rosario University & Barraquer Institute of America, Bogota, Colombia

FELLOWSHIP
Moorfield Eye Hospital, London
University of California San Diego

SPECIALTY
Cornea and Dry Eye

Pamela A. Hoo, OD

OPTOMETRY SCHOOL
Southern California College of Optometry at Marshall B. Ketchum University

Caitlin Jomoc, OD

OPTOMETRY SCHOOL
Midwestern University Arizona College of Optometry

Philip Kim, OD

OPTOMETRY SCHOOL
Nova Southeastern University

Anne B. Lam, OD

OPTOMETRY SCHOOL
Southern California College of Optometry at Marshall B. Ketchum University

Esmeralda McClean, OD

OPTOMETRY SCHOOL
New England College of Optometry

SPECIALTY
Ocular Disease

Lianne Mizoguchi, OD

OPTOMETRY SCHOOL
The Ohio State University

Tracy Moor, OD

OPTOMETRY SCHOOL
Columbus and Chillicothe VA Medical Centers

SPECIALTY
Ocular Disease

Andrew Vo, OD

OPTOMETRY SCHOOL
University of California Berkeley

RESIDENCY
Southern California College of Optometry at Marshall B. Ketchum University

SPECIALTY
Specialty Contact Lens

Carol Yu, OD

OPTOMETRY SCHOOL
University of California Berkeley

RESIDENCY
Nova Southeastern University

SPECIALTY
Specialty Contact Lens and Ocular Disease

NOT PICTURED:
Lara D. Hustana, OD

OPTOMETRY SCHOOL
Midwestern University Arizona College of Optometry

SPECIALTY
Ocular Disease
Resident Training Program

The UC San Diego ophthalmology residency training is a three-year program with 12 resident physicians (four per year of training).

Our highly selective residency program receives over 400 applications per year from throughout the country to fill four positions. The program is known for its outstanding clinical and surgical training, as well as the value placed on scholarships and compassionate patient care. Our residents are among the brightest and most motivated, and continue to be high achievers during and after their training.

As a result, graduating residents are regularly chosen for competitive post-residency Fellowship training in various subspecialties of Ophthalmology, such as Cornea, Glaucoma, Ophthalmic Plastic and Reconstructive Surgery and Retina at the Shiley Eye Institute. Under the supervision of the renowned Shiley faculty, residents learn to care for patients, from common to very rare eye conditions.

With departmental support, residents also participate in the many cutting-edge research opportunities available in the UC San Diego Viterbi Family Department of Ophthalmology and present their work at national meetings such as the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. The UC San Diego Ophthalmology Residency Training Program was recently recognized by the national accrediting body, the Accreditation Council for Graduate Medical Education, with a commendation on the excellence of the Residency Program and its faculty.

PGY-4 Residents
Aimee Chang, MD
Liane Dallalzadeh, MD
Lingling Huang, MD, PhD
Mark C. C. Lin, MD

PGY-3 Residents
Justin Arnett, MD
Medi Eslani, MD
Jenny Q. Hu, MD
Maya Yamane, MD

PGY-2 Residents
Helena Gali, MD
Andrew Lin, MD
Rafaella Penteado, MD
George Villatoro, MD
Shiley Eye Institute offers world-class fellowships in cornea, glaucoma, ophthalmic plastic and reconstructive surgery, pediatric ophthalmology, and retina. Fellows are exposed to expert training in both the clinical and research settings. Many assume prominent academic positions around the world as well as practicing as outstanding clinicians in the global ophthalmic community.

GLAUCOMA

- **Alireza Kamalipour, MD**
- **Takashi Nishida, MD, PhD**
- **Golnoush Mahmoudi Nezhad, MD, MPH**
- **Vahid Mohammad Zadeh, MD**
- **Joo Youn Shin, MD, PhD**
- **Jo-Hsuan (Sandy) Wu, MD**
- **Adeleh Yarmohammadi, MD**
- **Andrea Yonge, MD**

**NOT PICTURED**

- **Seyed Pourya Hoseini Alinodehi, PhD**
- **Na Young Lee, MD, PhD**
- **Gabriela Avila Mendoza, MD**

RETINA

- **Daniel Deussen, MD, MSc**
- **Carlo Galang, MD**
- **Fritz Kalaw, MD**
- **Alexa Li, MD**
- **Etienne Schonbach, MD**
- **Delu Song, MD**
- **Alexandra Warter, MD**
- **Shaden Handy Fathy Yassin, PhD**

**NOT PICTURED**

- **Hailey Robles-Holmes, MD**
- **Shikha Pachauri, PhD**

CORNEA

- **James Bailey, MD**
- **Samuel Burke, MD**

OCULOPLASTICS

- **Michelle Ting, MD**
- **Nicole Topilow, MD**

**NOT PICTURED**

- **Jin Sook Yoon, MD, PhD**

PEDIATRICS

- **Aaron Winter, MD**

**NOT PICTURED**

- **Gabriela Avila Mendoza, MD**
Graduation

GRADUATION OF RESIDENTS & FELLOWS

On June 21, 2022, the Viterbi Family Department of Ophthalmology and Shiley Eye Institute graduated outstanding residents and fellows with a virtual and socially distanced ceremony in the Shiley Conference Room.

Graduating Residents
Aimee Chang, MD (Co-Chief, Quality Assurance)
Liane Dallalzadeh, MD (Co-Chief, Academics)
Lingling Huang, MD, PhD (Co-Chief, Research)
Mark Lin, MD (Co-Chief, Administration)

Graduating Fellows
Michelle Ting, MD (Oculoplastics)
Aaron Winter, MD (Pediatric Ophthalmology)
James Bailey, MD (Cornea)
Samuel Burke, MD (Cornea)
Alexandria Li, MD (Retina)
Adeleh Yarmohammadi, MD (Glaucoma)
Andrea Yonge, MD (Glaucoma)
Vahid Mohammadzadeh, MD (Glaucoma Research)
Eleonora Micheletti, PhD, OD (Glaucoma Research)

GRADUATION AWARDS

The ninth annual Lamont Ericson, MD Award for Outstanding Patient Care by a Resident was awarded to Mark Lin, MD by Residency Director, Jeffrey Lee, MD. Dr. Ericson was an outstanding former resident in the department who passed away in 2007 at a young age. The department is grateful that Dr. Ericson’s family has supported his memory in this special way.

The inaugural Lanna Cheng Ophthalmology Innovation Award in recognition of outstanding innovation in research in the retina was given to Shyamanga Borooah, MD, PhD.

The inaugural Lanna Cheng Ophthalmology Innovation Award in recognition of outstanding innovation in research in ophthalmic reconstructive and oculofacial plastic surgery was given to Nicole Topilow, MD.

The Whitehill Teaching Award from the UC San Diego Health Sciences Academy of Clinical Scholars was given to Doran Spencer, MD, PhD. The recipient is chosen by the Chief Residents and given to an Assistant or Associate level faculty member who best exemplifies compassionate bedside manners for learners to emulate, serves as an advocate for trainees, and encourages and facilitates clinical, translation or basic science research projects.

Award for Teaching by a Resident Rounds & Didactics
Liane Dallalzadeh, MD

OKAP Teaching Award
Liane Dallalzadeh, MD

Outstanding Academic Achievement Award (OKAP)
Lingling Huang, MD, PhD
Justin Arnett, MD

Outstanding Surgical Teaching
David Granet, MD
Bobby Korn, MD, PhD

Outstanding Clinical Teaching
Sasan Moghimi, MD

Award for Teaching by a Fellow
Alexa Li, MD

Teaching Excellence Award
Cole Ferguson, MD
Education: Physicians

2022 OPHTHALMOLOGY UPDATE

The 2022 Ophthalmology Update, sponsored by the Viterbi Family Department of Ophthalmology and the Shiley Eye Institute at UC San Diego, was held virtually on February 26, 2022. Natalie Afshari, MD, David Granet, MD, Eric Nudleman, MD, PhD, Don Kikkawa, MD and Robert N. Weinreb, MD served as Program Moderators. The interdisciplinary faculty of ophthalmic subspecialists reviewed the continuing progress, latest surgical techniques, innovative ideas and cutting-edge translational research in ophthalmology.
education: physicians

virtual grand rounds

the community and sei alumni are also invited to the departmental weekly grand rounds on monday afternoon. the grand rounds consist of a special lecture from a prominent physician scientist from around the world and case presentations with moderated discussion. interesting eye diseases, treatment dilemmas and surgical challenges are often the theme. due to the covid-19 pandemic, the grand rounds became virtual to follow safety guidelines. cme credits are given for this event as well.

january 10, 2022
moderated by robert n. weinreb, md
guest lecturer: james tsai, md
president - new york eye and ear infirmary of mount sinai, delafield-rogers professor and chair department of ophthalmology, icahn school of medicine at mount sinai
title: “new innovative directions in glaucoma detection and management”

january 24, 2022
moderated by don o. kikkawa, md
guest commentator: samuel lance, md
associate clinical professor, director, adult craniomaxillofacial surgery, director, plastic surgery residency program, ucsd division of plastic surgery

january 31, 2022
moderated by natalie afshari, md
guest commentator: gabriel valerio, md
lcdr, mc, usn, refractive surgery advisor for navy ophthalmology, program director, navy refractive surgery san diego, assistant professor of surgery, usuhs, cornea, external disease & refractive surgery, naval medical center san diego

title: “new innovative directions in glaucoma detection and management”

february 7, 2022
moderated by robert n. weinreb, md
guest lecturer: peter savino, md
professor of ophthalmology & neurosciences, viterbi family department of ophthalmology, shiley eye institute, uc san diego
title: “things that could bite you”

march 7, 2022
moderated by william freeman, md

march 14, 2022
moderated by robert n. weinreb, md

march 21, 2022
moderated by natalie afshari, md
guest lecturer: mark j. mannis, md
fosse endowed chair in vision science research, professor and chair, department of ophthalmology & vision science, university of california davis eye center
title: “keratoplasty: past, present, and “back to the future”

march 28, 2022
moderated by doran spencer, md, phd

april 11, 2022
moderated by don o. kikkawa, md
guest lecturer: parag sanghvi, md, msph
vice chair and professor, department of radiation medicine and applied sciences, uc san diego health
“the role of radiotherapy in orbital and ocular tumors”

april 18, 2022
moderated by william freeman, md

may 9, 2022
moderated by david granet, md
guest lecturer: ben wiggins, md, mha
president, american academy of ophthalmology
title: “the changing demography of ophthalmology practice”

september 12, 2022
moderated by doran spencer, md, phd
September 19, 2022
Moderated by William Freeman, MD
Guest Lecturer: Amani Fawzi, MD, FARVO
Cyrus Tang and Lee Jampol Professor of Ophthalmology
Professor, Department of Ophthalmology, Feinberg School of Medicine, Northwestern University
Title: “Vascular Imaging In Diabetic Retinopathy: What Have We Learned”

October 10, 2022
Moderated by Doran Spencer, MD, PhD
Guest Lecturer: James Walsh, MD, PhD
Instructor, Ophthalmology and Visual Sciences
Washington University
Title: “Posterior Uveitis: The Contribution of Local Immunity”

November 7, 2022
Moderated by Peter Savino, MD

November 14, 2022
Moderated by Nathan Scott, MD
Guest Lecturer: J. William Harbour, MD
Professor and Chairman
The David Bruton, Jr. Chair in Ophthalmology
Department of Ophthalmology
UT Southwestern Medical Center
Title: “Recent Breakthroughs in the Management of Uveal Melanoma”

VISION RESEARCH LECTURES
The Vision Research Lecture Series addresses the latest advances in vision science and clinical ophthalmology. Each presentation features UC San Diego Department of Ophthalmology’s faculty, as well as a selection of leading vision scientists from around the globe. These lectures are held in the Shiley Eye Institute Education Center.

January 4, 2022
Hosted by Derek Welsbie, MD, PhD
Guest Lecturer: Pradeep Ramulu, MD, PhD
Professor of Ophthalmology
Wilmer Eye Institute, Johns Hopkins Hospital
Title: The Complexity of Addressing Glaucoma Disability

January 12, 2022
Hosted by Robert N. Weinreb, MD
Guest Lecturer: Randy Craven, MD, PhD
Medical Director, AbbVie
Title: Tenon’s Tissue and Glaucoma Surgery

January 13, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Monica M. Jablonski, PhD, FARVO
Professor, Department of Ophthalmology
Department of Anatomy and Neurobiology
The University of Tennessee Health Science Center
Title: Bidirectional Translation: Novel Preclinical Models of Glaucoma and New Therapeutics

January 19, 2022
Hosted by Linda M. Zangwill, PhD
Guest Lecturer: Mae Gordon
Professor, Ophthalmology and Visual Sciences
Washington University School of Medicine
Title: The Ocular Hypertension Treatment Study: A 20 Year Update

January 20, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Adam Rule, PhD
Assistant Professor in the Information School
University of Wisconsin-Madison
Title: The Composition of Clinical Notes

January 27, 2022
Hosted by Radha Ayyagari, PhD and Shyamanga Borooah, MBBS, MRCP (UK), MRCSEd, FRCOphth, PhD
Guest Lecturer: Patrick Yu-Wai-Man, PhD, FRCPath, FRCOphth
Professor, Department of Clinical Neurosciences
University of Cambridge
Title: Inherited Optic Neuropathies – An Update

February 28, 2022
Guest Lecturer: Kaweh Mansouri, MD MPH
Consultant Ophthalmologist
Montchoisi Eye Clinic, Lausanne, Switzerland
Title: Does MIGS Work? Where Are The Data?

March 9, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Michelle Hribar, PhD, MS
Assistant Professor of Medical Informatics and Clinical Epidemiology,
School of Medicine
Oregon Health and Science University
Title: Using EHR Data to Improve Patient Compliance: A Case Study for Amblyopia Patients

March 16, 2022
Hosted by Jiun Do, MD, PhD
Guest Lecturer: Benjamin Xu, MD, PhD
Assistant Professor of Ophthalmology
University of Southern California Roski Eye Institute
Title: Treating Primary Angle Closure Disease: What’s the Evidence?

March 31, 2022
Hosted by Robert N. Weinreb, MD
Guest Lecturer: Xin Duan, PhD
Assistant Professor, Department of Ophthalmology
University of California San Francisco
Title: Selective Retinal Neurons and Circuits in Neuroprotection and Axon Regeneration

April 6, 2022
Hosted by Sasan Moghimi, MD
Guest Lecturer: Kouros Nouri-Mahdavi, MD
Professor-in-Residence, Ophthalmology
University of California Los Angeles
Title: Challenges of OCT Imaging in Myopia and Diagnostic Implications in Glaucoma

April 13, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Cecilia S. Lee, MD, MS
Associate Professor, Director of Clinical Research
University of Washington
Title: Understanding the Connection Between the Aging Eyes and the Aging Brain

May 4, 2022
Hosted by Derek Welsbie, MD, PhD
Guest Lecturer: David S. Friedman, MD, PhD, MPH
Professor of Ophthalmology
Harvard Medical School
Director, Glaucoma Service
Massachusetts Eye and Ear

May 11, 2022
Hosted by Robert N. Weinreb, MD
Guest Lecturer: Tomas Grippo, MD
Hospital Aleman
Buenos Aires, Argentina
Title: Micropulse Laser Cyclophoto-coagulation

Guest Lecturer: Gulab Zode, PhD
Associate Professor, Pharmacology & Neuroscience
North Texas Eye Research Institute
Title: Targeting Trabecular Meshwork Pathology for the Treatment of Glaucoma

May 18, 2022
Hosted by Sasan Moghimi, MD
Guest Lecturer: Arsham Sheybani, MD
Associate Professor of Ophthalmology and Visual Sciences
Washington University, School of Medicine
Title: Malignant Glaucoma, Rational for Modern Day Management

Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Kerry Goetz, MS
Associate Director, NEI Office of Data Science & Health Informatics
National Eye Institute
Title: National Eye Institute Office of Data Science & Informatics

June 9, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Thanh V. Hoang, PhD
Postdoctoral Fellow
Johns Hopkins University School of Medicine
Title: Reprogramming Mammalian Glial Cells to Regenerate Neurons

September 9, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Patricia Becerra, PhD
Senior Investigator
National Institutes of Health
Title: PEDF Deficiency Increases the Susceptibility to Retinal Degeneration and Induces Senescence in the RPE

October 6, 2022
Hosted by Sasan Moghimi, MD
Guest Lecturer: Arsham Sheybani, MD
Associate Professor of Ophthalmology and Visual Sciences
Washington University, School of Medicine
Title: UC San Diego and Washington U Joint Glaucoma Rounds

November 10, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Michael V. Boland, MD, PhD
Associate Professor of Ophthalmology
Harvard Medical School
Site Director, Mass Eye and Ear, Lexington Medical Director, Practice Innovation for Ophthalmology
Massachusetts Eye and Ear
Title: Advancing Academic Opthalmology with Information Technology

November 17, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Nawajes Mandal, PhD
Associate Professor
Department of Ophthalmology
Department of Anatomy and Neurobiology
Hamilton Eye Institute
University of Tennessee Health Science Center
Title: Sphingolipids in the Pathobiology of Eye Diseases and their Translational Relevance

December 8, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Sheikh Amer Riazuddin, PhD, MS
Associate Professor of Ophthalmology
Wilmer Eye Institute, Johns Hopkins University School of Medicine
Title: The Promise of Molecular Genetics: Structure, Function, and Personalized Medicine

December 13, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Alvin Liu, MD
Assistant Professor of Ophthalmology
Johns Hopkins University
Title: Artificial Intelligence Initiatives at Johns Hopkins Medicine and the Wilmer Eye Institute
## Grants 2022

<table>
<thead>
<tr>
<th>Division</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornea</td>
<td>Natalie A. Afshari, MD</td>
<td>Whole Exome Sequencing for Variant Discovery in Fuchs Endothelial Corneal Dystrophy</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Sally Baxter, MD</td>
<td>Multi-Modal Health Information Technology Innovations for Precision Management of Glaucoma</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Sally Baxter, MD</td>
<td>Supplemental Graduate Student Support for Multi-modal Health Information Technology Innovations Project</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Sally Baxter, MD</td>
<td>OT2 NIH Bridge to Artificial Intelligence (Bridge2AI) Program - Skills Development</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Mark Christopher, PhD</td>
<td>Deep Learning Approaches to Detect Glaucoma and Predict Progression from Spectral Domain Optical Coherence Tomography</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Jiun Do, MD, PhD</td>
<td>Development of Optic Nerve Relays to Restore Retinofugal Connections</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Jiun Do, MD, PhD</td>
<td>Optic Nerve Relays for the Restoration of Visual Function</td>
<td>Glaucoma Research Foundation</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Jiun Do, MD, PhD</td>
<td>Stem Cell-Derived Optic Nerve Relays to Restore Vision</td>
<td>America Glaucoma Foundation</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Alex Huang, MD, PhD</td>
<td>Dynamic Variable Aqueous Humor Outflow and Glaucoma Therapies in the Human Eye</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Alex Huang, MD, PhD</td>
<td>Exercise Countermeasure to Prevent Ocular Structural and Functional Changes in a Terrestrial Model of SANS</td>
<td>NASA</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Alex Huang, MD, PhD</td>
<td>iSAFE (Investigating Structure and Function of the Eye)</td>
<td>NASA</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wonkyu Ju, PhD</td>
<td>Mitochondrial Protection in Glaucomatous Optic Neuropathy</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wonkyu Ju, PhD</td>
<td>Mitochondrial Protection in Glaucomatous Optic Neuropathy (Seahorse Analyzer)</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wonkyu Ju, PhD</td>
<td>AAV-AIBP Therapy for Alzheimer's Disease</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wonkyu Ju, PhD</td>
<td>Neuroprotective Role of Sirt6 in Glaucoma</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wonkyu Ju, PhD</td>
<td>CXCR3-mediated Cell-cell Communication during Glaucoma</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wonkyu Ju, PhD</td>
<td>Reversing Microglial Inflammarafs and Mitochondrial Dysfunction in Alzheimer's</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Sasan Moghimi, MD</td>
<td>Racial Differences in Smoking-related Glaucoma Progression: Effect on Neural and Vascular Tissue</td>
<td>TDRP</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Sasan Moghimi, MD</td>
<td>Monitoring of Glaucoma Patients in Advanced Disease</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Robert N. Weinreb, MD</td>
<td>Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Robert N. Weinreb, MD</td>
<td>iGLAMOUR Study: Innovations in Glaucoma Adherence and monitoring of Under-Represented minorities</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Robert N. Weinreb, MD</td>
<td>Ophthalmology and Visual Sciences Career Development K12 program</td>
<td>National Institutes of Health/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Robert N. Weinreb, MD</td>
<td>Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography. May 2018 - April 2022</td>
<td>National Institutes of Health/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Robert N. Weinreb, MD</td>
<td>Unrestricted and Challenge Grant - Research to Prevent Blindness. January 2018 - December 2023</td>
<td>Research to Prevent Blindness</td>
</tr>
<tr>
<td>Division</td>
<td>Principal Investigator</td>
<td>Title</td>
<td>Funding Agency</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Derek S. Welsbie, MD, PhD</td>
<td>Kinase Multitargeting for Glaucoma Neuroprotection</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Derek S. Welsbie, MD, PhD</td>
<td>High-Throughput Functional Genomic Screening in Retinal Ganglion Cells</td>
<td>Glaucoma Research Foundation</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Derek S. Welsbie, MD, PhD</td>
<td>Developing an Optic Nerve Relay for Vision Restoration</td>
<td>Research to Prevent Blindness</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Derek S. Welsbie, MD, PhD</td>
<td>Development of Small Molecule and Gene Therapy Approaches to Inhibit Dual Leucine Zipper Kinase and Accessory Pathways for Retinal Ganglion Cell Neuroprotection</td>
<td>Oriole Therapeutics, Inc.</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Kinase Multitargeting for Glaucoma Neuroprotection (Administrative)</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>OT2 NIH Bridge to Artificial Intelligence (Bridge2AI) Program - Data Generation</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Multimodal Artificial Intelligence to Predict Glaucomatous Progression and Surgical Intervention</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced Diseases PI: Linda Zangwill, PhD, Co-I: Robert N. Weinreb, MD, Co-I: Christopher Bowd, PhD, NIH, March 2017 – February 2022</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Translational Vision Research Training at UCSD PI: Linda Zangwill, PhD, Co-I: Radha Ayyagari</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Dietary Interventions to Improve Vision</td>
<td>Krupp Endowment</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>P30-Center Core Grant for Vision Research PI: Linda Zangwill, PhD, PI: William R. Freeman, MD, Co-I: Dirk-Uwe G. Bartsch, PhD, Co-I: Lingyun Cheng, MD, NIH, September 2018 – August 2022</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening</td>
<td>NIH/DRCR</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>AI-Based Identification of Rapid Glaucoma Progression to Guide Clinical management and Accelerate Clinical Trials</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Forecasting Disease Progression using Artificial Intelligence</td>
<td>Glaucoma Research Foundation</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Linda Zangwill, PhD</td>
<td>Improve OCT Detection of Optic Nerve Head (ONH)</td>
<td>GMOPC</td>
</tr>
<tr>
<td>Oculo-</td>
<td>Don O. Kikkawa, MD</td>
<td>Gene Expression in Nonspecific Orbital Inflammation Disease Co-I: Don O. Kikkawa, MD NIH, September 2016 - August 2021</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>plastic</td>
<td>Iliana Molina, MS</td>
<td>UC San Diego Shiley EyeMobile</td>
<td>Price Foundation</td>
</tr>
<tr>
<td>Pediatric</td>
<td>Jolene Rudell, MD, PhD</td>
<td>The Effects of Bupivacaine on Extraocular Muscles as a Treatment for Strabismus</td>
<td>Strabismus Research Foundation</td>
</tr>
<tr>
<td>Pediatric</td>
<td>Jolene Rudell, MD, PhD</td>
<td>Role of Fibroblast Growth Factor Signaling in a Genetic Model of Strabismus</td>
<td>UCSD/ACTRI</td>
</tr>
<tr>
<td>Retina</td>
<td>Radha Ayyagari, PhD</td>
<td>Identification of the Elusive Genetic Causality of Inherited Retinal Degenerations (IRDs)</td>
<td>The Foundation Fighting Blindness</td>
</tr>
</tbody>
</table>
## Grants 2022

<table>
<thead>
<tr>
<th>Division</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retina</td>
<td>Radha Ayyagari, PhD</td>
<td>Molecular Basis of Hereditary Retinal Degenerations</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Radha Ayyagari, PhD</td>
<td>Molecular Mechanism Underlying Late-onset Retinal/Macular Degeneration</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Radha Ayyagari, PhD</td>
<td>Unraveling the Molecular Pathology of Retinal Degeneration through Single Cell Genomics</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Dirk-Uwe Bartsch, PhD</td>
<td>Mechanistic-Based Non-Invasive Assessment of Retinal Damage in HAART Era</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Shyamanga Borooah, MD, PhD</td>
<td>Combining the Utility of Human Induced Pluripotent Stem Cell Modeling and CRISPR-Cas9 Gene Editing with Adenoassociated Virus Vector Gene Delivery to Develop and Optimize Novel Gene Editing in Inherited RPE Disease</td>
<td>The Foundation Fighting Blindness</td>
</tr>
<tr>
<td>Retina</td>
<td>Napoleone Ferrara, MD</td>
<td>Long Novel-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders; Co-I: Eric Nudleman, MD, PhD</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric D. Nudleman, MD, PhD</td>
<td>Role of PDLIM1 in Retinal Vascular Leakage and Proliferation</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric D. Nudleman, MD, PhD</td>
<td>Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric D. Nudleman, MD, PhD</td>
<td>Stein Innovation Award</td>
<td>RPB</td>
</tr>
<tr>
<td>Retina</td>
<td>Nicholas Oesch, PhD</td>
<td>Computing Luminance and Contrast in Prosthetically Driven Retina</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Retina</td>
<td>Christopher Toomey, MD, PhD</td>
<td>Robert Machemer MD and International Retinal Research Foundation Fellowship</td>
<td>Robert Machemer Foundation</td>
</tr>
<tr>
<td>Stem Cell</td>
<td>Karl Wahlin, PhD</td>
<td>Endogenous Generation of Cone Photoreceptors to Increase Light Responses in Foveal Hypoplasia</td>
<td>Vision of Children</td>
</tr>
<tr>
<td>Stem Cell</td>
<td>Karl Wahlin, PhD</td>
<td>Pluripotent Stem Cell Derived 3D Retinas for Studies of Early Onset Retinal Degeneration</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Stem Cell</td>
<td>Karl Wahlin, PhD</td>
<td>Dissecting the Biochemical Role of Epigenetically Modified Regulatory Sequences within the Genomes of Retinal Neurons (A1)</td>
<td>James Madison University; NIH/NEI as Prime</td>
</tr>
<tr>
<td>Stem Cell</td>
<td>Karl Wahlin, PhD</td>
<td>Correlating Genomic AMD Risk Variants with Lipid Composition and Phagocytic Function of Patient-Derived Induced Pluripotent Stem Cell (iP-SC)-derived Retinal Pigment Epithelium (RPE)</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Stem Cell</td>
<td>Karl Wahlin, PhD</td>
<td>Endogenous Repair in a Human 3D Retinal Organoid Model of Leber Congenital Amaurosis</td>
<td>NIH/NEI</td>
</tr>
</tbody>
</table>
### Clinical Trials 2022

<table>
<thead>
<tr>
<th>Division</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornea</td>
<td>Natalie A. Afshari, MD</td>
<td>Phase 1/2 Study for Autologous Human CD34+ Hematopoietic Stem Cells Ex Vivo Transduced 67 with pCCL-CTNS Lentiviral Vector for Treatment of Cystinosis</td>
<td>CIRM</td>
</tr>
<tr>
<td>Cornea</td>
<td>Natalie A. Afshari, MD</td>
<td>A Phase I/II Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Cornea</td>
<td>Natalie A. Afshari, MD</td>
<td>Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation</td>
<td>Dizal Pharmaceuticals</td>
</tr>
<tr>
<td>Cornea</td>
<td>Natalie A. Afshari, MD</td>
<td>Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Rvntansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma</td>
<td>National Cancer Institute (NCI)</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Christopher Heichel, MD</td>
<td>A Thirteen-year Study of the Indications and Visual Outcomes of Capsular Tension Ring Implantation in Cataract Surgery 2016</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Christopher J. Bowd, PhD</td>
<td>A0081096 Prospective Randomized 12 233k Controlled Study of Visual Field Change in Subjects with Partial seizures Receiving Pregabalin or Placebo - Pfizer Inc</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Andrew Camp, MD</td>
<td>The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension Pl: Andrew S. Camp MD</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Andrew Camp, MD</td>
<td>Efficacy and Safety of AbGn-168H in Patients with Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Andrew Camp, MD</td>
<td>Effects of the Body Position on Episcleral Venous Pressure and Intraocular Pressure in Glaucoma.</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Andrew Camp, MD</td>
<td>XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold Standard Pathway Study (GPS)</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Andrew Camp, MD</td>
<td>An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with open Angle Glaucoma or Ocular Hypertension</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Andrew Camp, MD</td>
<td>A Prospective, Double-masked, Randomized, Multicenter, Placebo Controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Japanese/Japanese American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States</td>
<td>Aerie</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Alex A. Huang, MD, PhD</td>
<td>A Phase IIb, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension</td>
<td>Santen Pharmaceutical</td>
</tr>
<tr>
<td>Division</td>
<td>Principal Investigator</td>
<td>Title</td>
<td>Funding Agency</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Robert Weinreb, MD</td>
<td>A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Latanoprostene Bunod and Timolol on Intraocular Pressure and retinal Blood Vessel Density in Patients with Ocular Hypertension or Primary Open Angle Glaucoma</td>
<td>Bausch &amp; Lomb</td>
</tr>
<tr>
<td>Oculoplastics</td>
<td>Catherine Liu, MD and Sally Baxter, MD, MSc, Sub-Investigator</td>
<td>A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA in Treating Patients with Chronic (Inactive) Thyroid Eye Disease</td>
<td>Horizon Therapeutics USA, Inc.</td>
</tr>
<tr>
<td>Pediatric Ophthalmology</td>
<td>Shira Robbins, MD</td>
<td>A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered with a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)</td>
<td>Eyenovia, Inc./Bausch &amp; Lomb</td>
</tr>
<tr>
<td>Retina</td>
<td>Shyamanga Borooah, PhD</td>
<td>Natural History Study of Patients with X-linked Retinal Dystrophy Associated with Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)</td>
<td>MeiraGTx UK II Ltd</td>
</tr>
<tr>
<td>Retina</td>
<td>Shyamanga Borooah, PhD</td>
<td>Phenotyping and Genotyping Patients with Achromatopsia in Preparation for Gene Therapy Trials</td>
<td>MeiraGTx UK II Ltd</td>
</tr>
<tr>
<td>Retina</td>
<td>Shyamanga Borooah, PhD</td>
<td>A Phase 2 Randomized Placebo-Controlled Double-Masked Study to Assess Safety &amp; Efficacy of Multiple Doses of IONIS-FB-LRX an Antisense Inhibitor of Complement Factor B in Patients w/GA 2nd to AMD</td>
<td>Syneos Health Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Shyamanga Borooah, PhD</td>
<td>Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A&gt;G in Intron 26 (IVS26) of the CEP290 Gene (&quot;LCA10-IVS26&quot;)</td>
<td>Editas Medicine</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular AMD [PORTAL]</td>
<td>Genentech, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration</td>
<td>Kodiak Sciences, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Phase 3 Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial to assess the Safety and Efficacy of Intravitreal Administration of ZIMURA™ (Complement C5 Inhibitor) in patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GATHER2)</td>
<td>IVERIC Biosciences</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration</td>
<td>AMGEN Pharmaceuticals</td>
</tr>
</tbody>
</table>
# Clinical Trials 2022

<table>
<thead>
<tr>
<th>Division</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration [PULSAR]</td>
<td>BAYER AG</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)</td>
<td>Alexion Pharma</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naive Macular Edema Secondary to Retinal Vein Occlusion [BEACON]</td>
<td>Kodiak Sciences, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naive Diabetic Macular Edema [GLEAM]</td>
<td>Kodiak Sciences, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>William Freeman, MD</td>
<td>A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of PEGCETACOPLAN in subjects with Geographic Atrophy 2nd to AMD [GALE]</td>
<td>Apellis Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric Nudleman, MD, PhD</td>
<td>A 2-year, Three-Arm, Multicenter, Randomized, Double-Masked, Multicenter, Phase III Study assessing the Efficacy and Safety of Brolucizumab vs Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTRHELP)</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric Nudleman, MD, PhD</td>
<td>A Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity (ROP)</td>
<td>Regeneron Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric Nudleman, MD, PhD</td>
<td>An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTE-ROP-1920 Study” [BUTTERFLYEYE]</td>
<td>Regeneron Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Eric Nudleman, MD, PhD</td>
<td>Testing Collagen Probes and Bispecific VEGF/Ang-2 Suppression</td>
<td>F. Hoffmann-La Roche LTD Genentech, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Doran Spencer, MD, PhD</td>
<td>A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-related Macular Degeneration [TENAYA]</td>
<td>Tarsier Pharma</td>
</tr>
<tr>
<td>Retina</td>
<td>Doran Spencer, MD, PhD</td>
<td>A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects with Active Non-infectious Anterior Uveitis including Subjects with Uveitic Glaucoma</td>
<td>Tarsier Pharma</td>
</tr>
</tbody>
</table>
Giving Opportunities

For over 30 years, the philanthropic support from generous individuals, foundations and corporations has provided the Shiley Eye Institute and Viterbi Family Department of Ophthalmology with valuable resources for patient care, research, education and community service. As a friend of the Department of Ophthalmology, there are several giving options for those who wish to contribute to our tradition of excellence.

Outright Gifts – Immediate Impact

Outright gifts of all sizes made with cash, check, credit cards, savings bonds, stocks, marketable securities or property provide immediate impact to our faculty and facility. If writing a check, please make payable to the “UC San Diego Foundation” and put the Shiley Eye Institute in the memo section. The check should be accompanied with a letter stating the focus of your donation and mail to

The Shiley Eye Institute, Mail Code 0946, 9415 Campus Point Drive, Room 241B, La Jolla, CA, 92037-0946
(Attention: Karen Anisko Ryan)

Annual Gifts – Circle of Sight

Started in 1996, the Circle of Sight is the Shiley Eye Institute’s recognition program that acknowledges donors who make annual gifts of $250 or more to support the greatest needs of the Department. Several times a year, the Shiley Eye Institute’s Circle of Sight members are invited to attend Vision Research Lectures and receptions where members get to personally know our faculty. The members are also ambassadors for the Shiley Eye Institute within the San Diego community. The Circle of Sight group is the backbone of many of our successful initiatives.

Planned Gifts – Your Vision for Tomorrow

Please consider a charitable bequest in your estate plan that will benefit the future of the Shiley Eye Institute and directly support the Viterbi Family Department of Ophthalmology. We would be pleased to provide you, your attorney, accountant or tax advisor with specific bequest language for inclusion in your will, trust or as a beneficiary of your retirement account – all of which can lessen the impact of taxes on your heirs or give you comfort of knowing that your assets will benefit those you leave behind.

Tribute Gifts – Acknowledge Someone Special

Contributions can be made in memory, honor or in celebration of a loved one or to commemorate a special occasion. Gifts can be made to honor a special physician, for ex-
ample, who has played a significant role in your eye health. Such a gift creates a legacy and memorializes the person by providing direct support to the Department.

**Matching Gifts – Double or Triple your Gift**

Many employers offer a matching gift program to their employees meaning that your donations are worth even more. All you need is a Matching Gift Form from your employer.

**Endowments – Gifts in Perpetuity**

A gift of endowment demonstrates your long-term commitment to the Viterbi Family Department of Ophthalmology since the fund is maintained in perpetuity. Your gift can support programs, lectures, awards, fellowships and Chairs. An endowment serves as an enduring legacy since it often bears the name of a donor or loved one.

**Gifts of Real Estate**

Making a gift of real estate is a generous and financially advantageous way to support Shiley Eye Institute. Many people have residential rental units or vacation homes that no longer serve their needs or have become too burdensome to maintain. Even commercial property and vacant land can be used as gifts to support Shiley’s programs. Real estate can be given as an outright gift or in a bargain sale; it can be used to create a retained life estate, a charitable gift annuity or a charitable remainder trust. There are many creative ways that your real estate can unlock financial security and provide tax benefits for you now while supporting Shiley Eye Institute and the programs that mean the most to you.

Every donation makes a direct impact on our patients, faculty, researchers, residents, fellows and staff, as well as the field of Ophthalmology. We cherish the partnership that we have developed with those generous members of the community who invest in us. There are also naming opportunities for gifts including: endowed chairs, laboratories, specialized ophthalmic clinics and research initiatives. We would welcome the opportunity to have a confidential conversation with you, so we clearly understand how you want your gift to be used.

**Achieve Your Philanthropic Goals & Provide Financial Benefits**

**NEW INFORMATION**

**Stocks and Securities:** A gift to the Shiley Eye Institute (SEI) of appreciated securities owned longer than one year can be deducted at fair market value and you will avoid paying capital gains tax on the appreciation.

**Qualified Charitable Distributions (QCD):** Whether or not you itemize, if you are at least 70½, you can make a QCD from your IRA to support SEI. A QCD is not included in your reportable taxable income and, if you take required minimum distributions, a QCD will count toward some or all of that amount. Remember that a QCD in 2023 can help you manage your financial situation in 2024, including your annual Medicare contributions and your overall tax picture.

**Charitable Gift Annuity (CGA):** With higher interest rates and inflation eroding your buying power, consider creating a CGA to provide a guaranteed lifetime income stream and immediate tax benefits. In fact, CGA annuity rates have just increased as of January 1, 2022 to their highest level in a decade. In addition, Congress passed SECURE Act 2.0 which allows for a one-time transfer of up to $50,000 from an IRA to a CGA (with certain restrictions).

**Donor Advised Fund:** Contribute to an existing fund and enjoy a tax savings when you itemize. You can then recommend a grant (or recurring grant) to the Shiley Eye Institute.

For more information about any of these gifting ideas, or for help in finding the best gift options for achieving your charitable goals, please contact Karen Anisko Ryan at kanisko@health.ucsd.edu or 858-534-8017. To learn how these giving options might affect your specific financial situation, please consult with your tax, legal or financial advisors.
The Shiley Eye Institute (SEI) at UC San Diego received another generous grant from Research to Prevent Blindness (RPB), the leading nonprofit organization supporting eye research to treat and prevent blindness. This most recent $115,000 unrestricted grant from RPB brings their total contribution to SEI at over $5,000,000 since 1984 when the first grant of $20,000 was awarded. SEI is one of 30 leading scientific institutions that RPB funds with these grants.

The grant supports eye research at the Viterbi Department of Ophthalmology. Robert N. Weinreb, MD, Distinguished Professor and Chair of the Viterbi Family Department of Ophthalmology, will allocate the funds to best serve the department’s research greatest needs.

“We are honored that RPB continues to support our groundbreaking vision research for almost 40 years,” stated Dr. Weinreb.

“Congratulations on this significant grant,” says Brian F. Hofland, PhD, President of Research to Prevent Blindness. “I look forward to seeing how SEI will use the RPB Unrestricted Grant to advance innovative research initiatives that build on their long tradition of excellence in vision research.”

For over 62 years, RPB has supported researchers who were associated with nearly every major breakthrough related to understanding and treatment of vision loss. More than $400 million have been provided by RPB in grants to support high-impact vision research.

VISIONARY CIRCLE

Members of the Visionary Circle are cumulative lifetime contributors of one million dollars or more to the Department of Ophthalmology. We appreciate their generosity.

Anonymous
Eleanor and John E.* Barbey, Jr.
Mr. and Mrs.* Woody Carter
David J. Dunn*
The Foundation Fighting Blindness
Hanna N. and Mark Gleiberman
Martin* and Enid* Gleich
Jean Hahn Hardy*
Hildyard Family Trust
Trude Kahn Hollander, MD*
Joan and Irwin Jacobs
Dorothy R. Kerrigan Trust
Tatiana* and Richard Kindell* Lansche
Michael Luzich, in honor of Norman and Carol Luzich
Arthur Murray and Carol-Faith Murray Trust
Nixon Visions Foundation
Irvin Olson and Rita A. Olson Trust
Marc Paskin
Anne F. Ratner*
Research to Prevent Blindness
Ruth L. Schulman*
Donald* and Darlene Shiley
Michael* and Rebecca Shiley
Patricia Shiley
Andrew J. Viterbi, Ph.D.
Frances Hamilton White*

*Deceased
The thirty-ninth annual Glaucoma Update was held virtually on October 26, 2022. Robert N. Weinreb, MD presented the latest trends in glaucoma treatments and research from the Shiley Eye Institute, Hamilton Glaucoma Center and around the world. Additional presenters included Glaucoma faculty: Jiu Do, MD, PhD, Alex Huang, MD, PhD and Derek Welsbie, MD, PhD.
With Appreciation

The honor roll for the Shiley Eye Institute and the Viterbi Family Department of Ophthalmology gratefully acknowledges donations from July 1, 2021 through June 30, 2022. Thank you to all of the individuals, foundations and corporations listed below.

**Gifts of $1 Million and Above**
- Hanna and Mark Gleiberman
- Tatiana A. and Richard Kindell Lansche Trust
- Nixon Visions Foundation
- Darlene V. Shiley
- Andrew J. Viterbi, PhD
- Tatiana A. and Richard Kindell Lansche Trust
- Nixon Visions Foundation
- Darlene V. Shiley
- Andrew J. Viterbi, PhD

**Gifts of $500,000 and $999,999**
- Anonymous
- Solange C. Isborn Trust

**Gifts of $100,000 and $499,999**
- Marilyn and David Anderson
- The Marian and Walter Trevor, Jane Trevor Fetter and Thompson Fetter Fund
- The Joan and Irwin Jacobs Fund of the Jewish Community Foundation
- Dr. Natasha Josefowitz
- Charlotte D. Laverents Family Trust
- The Martha P. Mack Foundation
- Ernest and Valerie Graham Trust
- Mr. and Mrs. Richard D. Thomas Trust

**Gifts of $50,000 to $99,999**
- Anonymous
- Wayne Green
- Heidelberg Engineering GmbH
- Laurie D. Munday
- Price Philanthropies Foundation
- Rudi Urlau

**Gifts of $25,000 to $49,999**
- Mr. and Mrs. Woody Carter
- Shiu-Chu Chiu

**Gifts of $1 Million and Above**
- Costa Wholesell Executive Match
- The Richard and Claudia* Libenson Fund of the Jewish Community Foundation
- Paul Margolis
- Halpin and Helen O’Reilly Charitable Trust
- Wilson and Jean Sexton
- Ann and Phil White

**Gifts of $10,000 to $24,999**
- Alcon Foundation
- The Altiere Family
- Farooq Azam
- Robert and Marjorie Beck Trust
- Dr. and Mrs. Stuart I. Brown
- Calori Family Giving Fund at the Rancho Santa Fe Foundation
- Bruce L. Deck
- Equinox Ophthalmic, Inc.
- The Diane and Elliot Feuerstein Fund of the Jewish Community Foundation
- Tully and Elise Friedman
- Buzz and Peg Gitelson
- Caroline and Daniel* Hamlin
- Laura and Carl Johnson
- Lanna C. Lewin
- Rosella and Cliff Louis
- The Estate of Barbara B. Martin
- The Gene and Taffin A. Ray Family Foundation
- Sari Simchoni and Al Blum

**Gifts up to $9,999**
- 52 & Convoy Corp. / Mr. and Mrs. Thompson Fetter
- Ashley Abecilla
- Cherree Adams
- Sarah E. Aghassi and Shahri Estakhry
- Francisco A. Aguling
- Dora Akuetteh, M.D.
- Diane Amatangelo
- Brian Andersen
- Trudy H. Anderson
- Mr. and Mrs. Cheem S. Ang
- Anonymous (30)
- Rustom and Daneesh Appoo
- Anthony Aranes
- MaryAnn Armijo
- Sally Aston
- Constance and Alexander Athens
- Teresita D. Aujero
- Maggie Awad
- Michell Babbitt
- John and Elizabeth Bagby
- John A. Bailey
- Thomas W. Baldauf in Memory of Janet M. Baldauf
- Christine and Gino Barra
- Francine and Marvin Bart
- William J. Bartle
- Mary L. Beebe
- Mr. and Mrs. Michael J. Bell
- Natalie M. Beller
- Jeannette Bellucci Charitable Fund
- Louise Benavidez
- Jennifer Berend
- Louise F. Bergman
- Silvia Berlin
- Dusty and Lynn Bernard
- Michele Bernique
- Arun K. Bhatia and Neera Bhatia
- Mr. and Mrs. Thomas L. Black
- Mrs. Elaine Bleau-Richards
- The Honorable and Mrs. Peter W. Bowie
- Miles and Patricia Bowler
- Dr. and Mrs. Michael R. Brans
- Alfred W. Brown
- Dennis W. Buckley
John J. Kiang
Annessa Kildare
Mrs. Carina Kipperman
Mr. and Mrs. Allan Kleinman
F. Stephen Kohl, MD
Hisako Koike
Phyllis Myra Kossar
Alexa and Bela Kozak
Mark Krey
Rosemarie Kubes
Kristen Kulchin
Bernard Kulchin and Paula Taylor
Blair La Claire
Mary Lagerlof Quinby
Elaine C. Lane
Robert L. Lane
Dr. and Mrs. Bruce R. Lawrence
Katherine Ann Lazzaro
Mark Leamy
Anne F. and Thomas C. Lee
Karen L. Lee and Joseph K. Drag
Mr. Jacques J. C. Lemire
Mr. and Mrs. Stephen A. Leon
Amir Lewis
Gene Lin
Tony and Mary Lovett
Claudia Lowenstein
Aileen M. Loyd
Patricia Lubarsky
James Luckow
Julie Lyon
Art Madrid
Mahmood F. Mafee, MD
Mr. and Mrs. Frederick Mandabach
Richard C. Mansfield
Larry Manzer
Robert and Susan Mardon
Juanito and Carmelita Mariano
Diane Martin
Todd and Brenda Mavis in Honor of Kylie Mavis
Jeff and Patty Maysent
Thomas McCulley
Deborah McCormac
Michael and Karen McCulley

Eileen and Anthony McKoy
Mr. and Mrs. Gary McMullen
Connie McNally
Robert W. McNamara
Christa McReynolds Fund
Valentina Mendiola
D. Asoka and Janine P. Mendis
Sonja D. Metzger
Thomas H. Metzger
Nancy Leitner
Theresa A. Miles
Jeffrey T. Miller
Thomas W. Miller
Ethelwyn Miyoshi
Kristi Molina
Rena C. Monge
Brian K. and Luisa D. Monson
Sarah A. Moore
Mr. and Mrs. S. W. Moore
Kira Moossazadeh
Dennis J. and Barbara R. C. Moran
Jonathan, Suzanne and Andrew Morris
Lois M. Mulcahey
Ty Mullan
Ian Mulligan
James Murphy
Tina Murphy
Elspeth and Jim Myer
Drusilla Myles
Katherine Nadler
Thomas and Mary Anne Nagel
Sam M. Naghavian
M. Naghieh
Glenn and Sherrie Naperskie
Roy Nasby
Dr. Narayanan Natarajan and Dr. Meenakshi
Kamaklamma
Ms. Janet Navigato
Jacalyn R. Nehrling
Ms. Katya Newmark and Mr. Matthew Costello
Mary Nguyen
Aithuy Nguyen
Toni Nickell
Gale and Ken Nill

Nishant Nishant
Toni K. Noblitt
Sherry Nolan
Mr. and Mrs. Philip Nordhues
Erma and Farley O’Brien Fund
Elena Oliva
Alfredo T. Ordonio
William R. Orvis and Tracy Dezenzo
Fran Osborn* and Tom Ryan
Babs Owca
Lorenza Pace
Audrey Palisoc
Victoria G. Pappas
Kimberly Parada
Ernie Peak
Joel and Ruth Perlin
David Perrin
Nikki Peterson
Justin Phillips
Angela Picillo
Josephine Pittrizzi
Trinele Pollard
Robert K. Poon
Gloria Garcia Posada
Kumara Prathipati
Laurie Price
Dr. and Mrs. John Proakis
Michael G. Qualls
Matt Quann
Maria D. Quiroz
Chris Quisimoro
Mary and Herb Rabe
Juanita Guadalupe Ramos
Al and Sharon Rappaport
Barbara Rasmussen
Mr. and Mrs. Gabriel Rayes
Eric Reese
James and Janet Respess
Parvin Rezainia
Jeffrey and Susan Richards
Drs. Anne and Paul Roberts
Donna E. Robinson
Rebeca Rodkin
Toni K. Roebuck
Inja Roh
Kathy and Jacques Romatier
Barbara Roper
Arlene Rosen
Mrs. Judith Rubenstein
Georgia and Blair Sadler
Mr. and Mrs. Norman Saks
John S. Salcido
Mr. and Mrs. Eli Alex Salsberg
Mrs. Sally F. Saltzstein
Cassandra and James Salvatore
Janis Sammartino and Herb Hoffman
LCDR John R. Savory, USN (Ret.)
John Scharler
Claire Schwan
Mr. and Mrs. Anthony Schwarz
Natalie Scrima
Mr. and Mrs. Ronald L. Sedita
Jonathan Seligman
Kobi M. Sethna
Sheely Family
Madelyn Diane Sheets*
Jerry and Patty Sheldon
Leonard Shulman
Patricia K. Shumway
Anne and Ronald Simon
Else K. Sjostrand Ottesen
Martha S. Sloan
John and Linda Small
Calvin Smith
Eugenia Smith
Kelsey Smith
Kyle and Yong Cha Smith
Stephen Smith
Kimberly G. Snyder
John and Socorro So
Darcel Spence
Sheila Steelman
Elizabeth and Lester Stiel
Joyce M. Suhl
Maria Swann, PhD
Mr. and Mrs. Ronald L. Tabor
Judith Tamkin
Van Tang
Fredricka Taubitz and Dennis M. Griffin
Patty Taylor
Dr. April Teitelbaum
Clyde and Penny Thornburg
Carol and Yashy Tohsaku
Carlos Tomaszewski
Carol Towne
Rose Tran / San Diego Vietnamese American Lions Club
Transformation Detail
John and Judy Turner
R. J. and Joy Urich
Enrique Vallejo
Jean Vesey
Bernice Viau
Viastat Inc.
Jocelyn and Dick Vortmann
Amalia Wadsworth
Margot Walk and Jerry Freeland
Jane E. Wallace
Ken Walter
Ann Watanabe
Mark Watson
Anthony L. Weaver
Janice T. Webb
Charles and Tara Wegner
Jo and Howard Weiner
Robert N. Weinreb, MD
Fran and Manuel Welchez
Robert E. Welk
Dayle West
Sharon White
Manuel Wiesner in Memory of Israel O. Wiesner
Caroleen Williams
Dr. Marcia Wishnick and Mr. Stanley Wishnick
Olive H. Withall
Wolf Management Consultants, Inc.
Susie Wolfe
Betty Wong
Bill Wright
Christy Yono
Barry Young
Steven S. Zank
Jose D. Zavalza
Yuzhen Zhu
Dr. and Mrs. Philip R. Ziring
James Zolin
Capt. Judy H. Zygowicz and Mr. John J. Zygowicz
Theresa Zysk

*Deceased

MEMORIALS

The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute at UC San Diego sadly acknowledges friends and key supporters who have passed away during the past year. They remain in our thoughts.

Suzanne Angelucci
Lori Carter
Carole Colby
Pearl Cutler
Maximiliana “Maxine” Davidson
Nomi Feldman
Howard Goldfeder
John J. Griffin
Dr. Daniel A. Hamlin
Paul Kalemkian
Claudia Libenson
Sally McMurray
Frances P. Osborn
Mary K. Sadler
Kenneth L. Unruh